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Ernest R. and Iris M. Eldred Professor of Law, Paul M. Herbert Law Center, Louisiana State University. JD Yale
Law School; BA, summa cum laude, Tufts University. This article was selected by international, interdisciplinary
peer review for presentation at “One Origin, One Race, One Earth: Genetics, Human Rights and the Next Phase of
Human Evolution,” which was hosted by the University of Calgary on November 15-17, 2007. My sincere
appreciation to event co-chairs Brian Seaman and Rose Geransar, and to all whose interactions greatly enriched this
manuscript. The article also has benefited from participation in several additional events and presentations, most
notably those given at a meeting hosted by Academia Sinica to launch the Taiwan Biobank, held in Taipei, Taiwan,
August 2007, and the 21st Century Trust forum on genomics held at the Wellcome Trust’s Sanger Institute,
Cambridge, England, in August 2006. The present version will be discussed at “Ancestry in Health and Medicine
Workshop: Expanding the Debate,” a roundtable event to be held in Toronto April 8-9, 2008. My appreciation to
the organizers of and participants in these events, and to colleagues Carl Coleman, Donna Gitter, Jonathan Kahn,
and David Winickoff, who shared their expertise in the field and, as always, were generous with their time. Their
contributions enriched this effort immensely. I also would like to thank Jim Figura and Damon Bowe for their
excellent research assistance and thoughtful editorial input.
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Oct. 14, 2007

[Dr. James Watson, co-discoverer of the structure of DNA,] says that he is “inherently
gloomy about the prospect of Africa” because “all our social policies are based on the
fact that their intelligence is the same as ours—whereas all the testing says not really’,
and I know that this “hot potato” is going to be difficult to address. His hope is that
everyone is equal, but he counters that “people who have to deal with black employees
find this not true”. He says that you should not discriminate on the basis of colour,
because “there are many people of colour who are very talented, but don’t promote them
when they haven’t succeeded at the lower level”. He writes that “there is no firm reason
to anticipate that the intellectual capacities of peoples geographically separated in their
evolution should prove to have evolved identically. Our wanting to reserve equal powers
of reason as some universal heritage of humanity will not be enough to make it so”.1

Oct. 18, 2007
The Federation of American Scientists (FAS) is outraged by the noxious comments of Dr.
James Watson that appeared in the Sunday [London] Times Magazine on October 14th.
At a time when the scientific community is feeling threatened by political forces seeking
to undermine its credibility it is tragic that one of the icons of modern science has cast
such dishonor on the profession.

1

Charlotte Hunt-Grubbe, The elementary DNA of Dr. Watson, THE SUN. TIMES, Oct. 14, 2007, at __.

2

The scientific enterprise is based on the promotion and proof of new ideas through
evidence, however controversial, but Dr. Watson chose to use his unique stature to
promote personal prejudices that are racist, vicious and unsupported by science.
While we honor the extraordinary contributions that Dr. Watson has made to science in
the past, his comments show that he has lost his way. He has failed us in the worst
possible way. It is a sad and revolting way to end a remarkable career.2

Oct. 18, 2007
Earlier this evening, the Cold Spring Harbor Laboratory Board of Trustees Decided to
Suspend the Administrative Responsibilities of Chancellor James D. Watson, Ph.D.,
pending further deliberation by the Board.
This action follows the Board’s public statement yesterday disagreeing with the
comments attributed to Dr. Watson in the October 14, 2007 edition of The Sunday Times
U.K.3

I. Introduction

2

The Federation of American Scientists Condemns the Comments of Dr. James Watson that Appeared in the Sunday
Times Magazine on Oct. 14th, available at http://fas.org/main/content.jsp?formAction=297&contentId=572.

3

Statement by Cold Spring Harbor Board of Trustees and President Bruce Stillman, Ph.D. Regarding Dr. Watson’s
Comments in The Sunday Times October 14, 2007, available at
http://www.cshl.edu/public/releases/07_statement2.html
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“Race” and “ethnicity” compel reaction.4 These concepts are social constructs,5 and
many commentators—drawing from a portfolio of disciplines that includes the natural sciences,
the social sciences, medicine, and law—argue that the human population groupings they form
4

The research, writing, and completion of this article coincides with a raw national debate over race, brought to a
simmer and then beyond by a series of controversies. Race and gender charged the Democratic primary race
between candidates Sen. Clinton and Sen. Obama. See Adam Nagourney, Democrats Vote Reveals Deep Split
Obama and Clinton Supporters Differ in Age, Race, and Gender, INT’L HERALD TRIB., Feb. 8. 2008, at 5. During
spring 2007, radio personality Don Imus was fired for racial and sexist remarks about the Rutgers University
women’s basketball team. See Dahleen Glanton, Civil Rights Group Has Eye on Prize of Peace: Nation, CHICAGO
TRIBUNE, Aug. 3, 2007 (page nos. not available), 2007 WLNR 14904150. Soon after, charges from an alleged rape
brought by an African American woman against Caucasian members of the Duke University male lacrosse team
were dropped and the prosecutor himself faced charges. See Glanton, Civil Rights Group, supra; David Zucchino,
The Nation: Ex-Duke Players Get New Apology, LA TIMES, July 27, 2007, at 13. Then, On September 20, the
nation’s attention was drawn to the small town of Jena, Louisiana, self-proclaimed to be “a nice place to call home,”
as more than 20,000 participated in a march led by the Reverand Jesse Jasckson and Al Sharpton. See Black
Leadership in America: Race, Justice and Jena, ECONOMIST, Sept. 2007, at 71, 2007 WLNR 18968014 (no author
identified). According to a report in the Economist,
At a high school assembly on August 30th [2006], a black student asked if he could sit under a shady tree on
campus where the white students usually hung out. The deputy principal said of course he could sit
wherever he wanted. The next day, two nooses dangled from the tree. They were quickly removed, and
the principal recommended that the three white students who hung them be expelled. But the school board
let them off with a suspension, arguing that the incident was just a childish prank. . . . . On December 4th a
black student named Mychal Bell jumped a white classmate from behind and knocked him out. Then he
and six others kicked him as he lay on the ground. He was released in time to go out that evening, but
retired home early complaining of pain. Five of the attackers were charged with attempted second-degree
murder. That caused an outcry, so the charges were reduced to second-degree battery, which still carries
heavy penalties. Mr. Bell was tried as an adult, though he was only 16 at the time of the attack. The
prosecutor says this was because he had been arrested four times before for violent offences. He was
convicted by an all-white jury. (Several blacks were summoned for jury duty, but non showed up.) . . . .
But a higher court threw out his conviction and ordered that he be tried as a juvenile.
Id. (page numbers unavailable). Even before the House Judiciary Committee could hold a hearing on the “Jena Six”
controversy (which took place on October 17, 2007), media reported on September 30 that a maintenance man found
a noose hanging in the Hempstead, Long Island police department. See Joe Gould & Carrie Melago, Noose Found
Hanging in L.I. Police Station, N.Y. DAILY NEWS, Sept 30, 2007, at 10; Dana Millbank, Justice Denied, Sharpton
Delayed, WASH. POST, Oct. 17, 2007 (page numbers unavailable), 2007 WLNR 20337642. On October 13, a noose
also was found hanging on the door of Professor Madonna Constantine, a black professor of psychology at
Columbia University, and other “noose incidents” started arising across the nation. See Lester Holt, Profile: In
Depth; Nooses, an Old Symbol of Hate, Making Comeback, NBC NEWS: NIGHTLY NEWS, Oct. 13, 2007 (page
numbers unavailable). These incidents were two of more than forty (40) noose hanging incidents across the country
during fall 2007. See Mark Potok, Luke Visconti, Barbara Frankel, & Nigel Holmes, The Geography of Hate,
N.Y.TIMES, Nov. 25, 2007, at P11.
5
See Pilar N. Ossorio, About Face: Forensic Genetic Testing for Race and Visible Traits, 34 J.L. MED. & ETHICS
277, 278-279 (2006); Statement of the American Sociological Association, The Importance of Collecting Data and
Doing Social Scientific Research on Race, American Sociological Association, available at <http://
www.asanet.org/governance/racestmt.html> (last visited Feb. 15, 2007); A. Smedley & B. D. Smedley, Race as
Biology is Fiction, Racism as a Social Problem is Real, 60 AMERICAN PSYCHOLOGIST 16-25 (2005). See also infra
notes 13-19 and accompanying text.
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are inconsistent with the scientific reality of human genetics.6 The fundamental argument is that
genetics groups us differently, often dramatically so, and it is scientifically and socially
misguided and contrary to ample U.S. law and policy, perhaps even illegal, to approach
contemporary population genetics with methodologies that embrace these constructs.7 While
the debate over race-based research has been of mixed opinion in the natural science and medical
disciplines,8 there is a discernable majority opinion among law academics that most race-based
research is wrong on multiple levels.9

6

See infra notes 63-98 and accompanying text.

7

See generally id.

8

Contrary science positions on race-based research were juxtaposed in the November 2004 issue of Nature
Genetics. See M. Bamshad, et al., Deconstructing the Relationship Between Genetics and Race, 5 NATURE GEN.
598-609 (2004); Francis Collins, What We Do and Don't Know About 'Race,' 'Ethnicity,' Genetics and Health at the
Dawn of the Genome Era, 36 NATURE GEN. SUPP. S13-S15 (2004); E. J. Parra, R. A. Kittles, M. D. Shriver,
Implications of Correlation Between Skin Color and Genetic Ancestry for Biomedical Research, 36 NAT. GENET.
SUPP. S54-S60 (2004); J. L. Mountain, N. Risch, Assessing Genetic Contributions to Phenotypic Differences Among
`Racial' and `Ethnic' Groups, 36 NAT GENET SUPP. S48-S53 (2004). See also, P. Sankar, Mildred K. Cho, C. M.
Condit, et al., Genetic Research and Health Disparities. 291 JAMA 2985-9 (2004); K. R. Merikangas, N. Risch,
Genomic Priorities and Public Health, 302 SCIENCE 599-601 (2003); E. G. Burchard, et al., The Importance of
Race and Ethnic Background in Biomedical Research and Clinical Practice, 348 N. ENG. J. MED. 1170-71 (2003):
R. S. Cooper, et al., Race and Genomics, 348 N. ENG. J.MED. 1166-67 (2003); N. A. Rosenberg, J. K. Pritchard, J.
L. Weber, et al., Genetic Structure of Human Populations, 298 SCIENCE 2381-5 (2002); N. Risch, et al.,
Categorization of Humans in Biomedical Research: Genes, Race and Disease, 3 GENOME BIOLOGY 1-12 (2002): R.
S. Schwartz, Racial Profiling in Medical Research, 344 N. ENG. J. MED. 1392-93 (2001); A. J. J. Wood, Racial
Differences in the Response to Drugs--Pointers to Genetic Differences, 344 N. ENG. J.MED. 1393-96 (2001). The
debate has intensified. See, e.g., Bibbins-Domingo, K., & Fernandez, ABiDil for Heart Failure in Black Patients:
Implications of the U.S. Food and Drug Administration Approval, 146 ANN INTERN MED 52-56 (2007); Guthery, S.
L., Salisbury, B. A., Pungliya, M. S., Stephens, J. C., & Bamshad, M, The Structure of Common Genetic Variation
in United States Populations, 81 AM J HUM GENET 1221-1231 (2007); Hafler, D. A., Compston, A., Sawcer, S.,
Lander, E. S., Daly, M. J., De Jager, P. L., et al., Risk Alleles for Multiple Sclerosis Identified by a Genomewide
Study, 357 N ENGL J MED. 851-862 (2007); Wu, Y.-R., Chen, C.-M., Chao, C.-Y., Ro, L.-S., Lyu, R.-K., Chang, K.H., et al., A Nonsynonymous SNP in Human Cytosolic Sialidase in a Small Asian Population Results in Reduced
Enzyme Activity: Potential Link With Severe Adverse Reactions to Oseltamivir, 17 CELL RESEARCH 357–362 (2007);
Neil Risch, Dissecting Racial and Ethnic Differences, 354 NEW ENG. J. MED. 408 (2006); M. Sinha, E. K. Larkin, R.
C. Elston, S. Redline, Self-Reported Race and Genetic Admixture, 354 N ENGL J MED 421-2 (2006); Daar, A. S., &
Singer, P. A, Pharmacogenetics and Geographical Ancestry: Implications for Drug Development and Global
Health, 6 NAT REV GENET. 241-246 (2005); H. Tang, T. Quertermous, B. Rodriguez, et al., Genetic Structure, SelfIdentified Raceethnicity, and Confounding in Case-Control Association Studies, 76 AM J HUM GEN. 268-75 (2005);
A. E. Shields, M. Fortun, E. M. Hammonds, et al., The Use of Race Variables in Genetic Studies of Complex Traits
and the Goal of Reducing Health Disparities: a Transdisciplinary Perspective, 60 AM PSYCHOLOGY 77-103 (2005).
Opponents argue that race lacks any reliable biological basis and, for genetics research to contribute meaningfully to
science and medicine, links between genes and disease should be made directly—for example, through single
nucleotide polymorphisms (“SNPs”) and other specific genetic characteristics associated with diseases and

5

This article proposes that responsible race-based genetics biomedical research—basic,
clinical and epidemiological—is possible, and even desirable. A primary premise for the
argument is that the concepts of race and ethnicity, like genetic science,10 are neither innately
good nor bad. Contrary to the dominant path followed by law academics,11 which is to approach
race-based research from anti-discrimination jurisprudence, this article approaches race-based
responses to medications. See generally M. Bamshad, Deconstructing, supra, at 509. See also infra note 46 and
accompanying text (SNPs addressed). Proponents argue that race does have a genetic basis—that, at the very least,
it influences lifestyle choices resulting in shared environmental exposures, and DNA links people to geographic
continents-regions that correspond with their self-identified racial classifications. See id. at 939-40. See, e.g., Race,
Ethnicity, and Genetics Working Group, The Use of Racial, Ethnic, and Ancestral Categories in Human Genetics
Research, 77 AM. J. HUM. GEN. 519-32 (2005); K Olden, SL White, Health-Related Disparities: Influence of
Environmental Factors, 89 MED. CLIN. NORTH AM. 721-38 (2005); E. Gonzalez Burchard, L. N. Borrell, S.
Choudhry, et al., Latino Populations: a Unique Opportunity for the Study of Race, Genetics, and Social
Environment in Epidemiological Research, 95 AM J PUBLIC HEALTH 2161-8 (2005). See also C. W. MILLS, THE
RACIAL CONTRACt (Ithaca, NY: Cornell University Press, 1997); P. KITCHER, IN MENDEL'S MIRROR:
PHILOSOPHICAL REFLECTIONS ON BIOLOGY 239-45 (2003).
9

See, e.g., Jonathan Kahn, Race-Ing Patents/Patenting Race: An Emerging Political Geography of Political
Geography in Biotechnology, 92 IOWA L. REV. 353 (2007); Erik Lillquist Charles A. Sullivan, Legal Regulations of
the Use of Race in Medical Research, 34 J. L. MED. ETHICS 535-547 (2006); Dorothy Roberts, Legal Constraints on
the Use of Race and Ethnicity in Biomedical Research, 34 J. L. MED & ETHICS 526-534 (2006); Sharona Hoffman,
“Racially-Tailored” Medicine Unraveled, 55 Am. U. L. Rev. 395-456 (2005); Erik Lillquist & Charles A. Sullivan,
The Law and Genetics of Racial Profiling in Medicine, 39 Harv. Civ. Rts-Civ. Lib. L. Rev. 442 391-483 (2004);
Jonathan Kahn, How a Drug Becomes 'Ethnic': Law, Commerce, and the Production of Racial Categories in
Medicine, 4 YALE J. HEALTH POL. L. & ETHICS 1-46 (2004). See also infra notes ___ and accompanying text. It is
important to note that the law literature includes contributions to the race-based genetics debate from authors whose
primary disciplines are in medicine and natural science, and they tend to be more receptive to, and even supportive
of, this research. See, e.g., Jay N. Cohn, The Use of Race and Ethnicity in Medicine: Lessons From the AfricanAmerican Heart Failure Trial, 34 J.L. MED. & ETHICS 552 (2006); Raj Bhopal, Race and Ethnicity: Responsible Use
from Epidemiological and Public Health Perspectives, 34 J. L. MED. & ETHICS 500 (2006), citing Raj Bhopal, Is
Research Into Ethnicity and Health Racist, Unsound, or Important Science?, 314 BRIT. MED. J. 1751-56 (1997), and
R. Bhopal, Ethnicity as a Variable in Epidemiological Research, 309 BRIT. MED. J. 327-28 (1994). See also
Margaret A. Winker, Race and Ethnicity in Medical Research: Requirements Meet Reality, 34 J.L. MED. & ETHICS
520 (2006); Morris W. Foster, Analyzing the Use of Race and Ethnicity in Biomedical Research from Local
Community Perspective, 34 J.L. MED. & ETHICS 508 (2006); Michael D. Ruel, Commentary, Using Race in Clinical
Research to Develop Tailored Medications, 27 J. LEGAL MED. 225 (2006).
10
Over the years, many have observed that the impact of genetic technology depends on how it is used. For
example, in the context of one of the two most fundamental healthcare essentials, food (the other being water),
genetic technology can be "democratically managed to the benefit of the most needy or skewed to the advantage of
specific groups that hold the vital political, economical and technological power." Illenia M. Demenina, Note and
Comment, Genetically Modified Foods in the International Arena: Trade labeling Controversy and the Importance
of Informed Consumer Choice, 2 B.Y.U. Int’l. & Mngt. Rev. 311 (2006), citing Sara J. MacLaughlin, Food for the
Twenty-First Century: An Analysis of Regulations for Genetically Engineered Food in the United States, Canada,
and the European Union, 14 IND. INT’L & COMP. L. REV. 375, 405 (2003).
11

See, e.g., Lillquist & Sullivan, Use of Race, supra note 9; Hoffman, Unraveled, supra note 9.

6

research with the goal of promoting thoughtful bioethics compliance and with the legal mindset
of inclusion analogous to the goals of affirmative action. This position is supported with
arguments based in research pragmatism, genetic science, and applied bioethics—namely
regulations to protect human subjects12 and the fundamental principals documented in the
Declaration of Helsinki13 and the Belmont Report.14
The article begins with a discussion of the natural science context forming the
background of the debate. Part II presents an overview of contemporary genetics research and
medicine with a focus on the increased appreciation of the subtleties and pervasiveness of
environmental influences on human genetics, and the heightened importance of population
genetics following completion of the map of the human genome.15 Part III summarizes the
ongoing debate in the sciences, medicine, and law over race-based genetics research. Part IV
12
In the United States, human subjects in research are protected through the Common Rule, 45 C.F.R. § 46 (2005),
and separate Food and Drug Administration regulations, 21 C.F.R. § 50.20 (2005). See also Bonnie M. Lee, U.S.
Food and Drug Administration, Comparison of FDA and HHS Human Subject Protection Regulations, 2000,
available at http://www.fda.gov/oc/gcp/comparison.html (last visited July 27, 2007).
13
World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human
Subjects (1964). The Declaration has been amended several times since 1964, including in 2002 and 2004. For
more information, visit the internet site of the World Medical Association, available at http://www.wma.net/e/ (last
visited Aug.2, 2007).
14

The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, at
http://ohsr.od.nih.gov/mpa/belmont.php3 (last visited Aug. 4, 2007).
15

The actual human genome map is available through the Encyclopedia of DNA Elements (“ENCODE”) Project, a
public research consortium launched by the National Human Genome Research Institute (“NHGRI”), information
about which is available at http://www.genome.gov/10005107 (last visited July 28, 2007), and related sites,
including UCSC Genome Bioinformatics, available at http://genome.ucsc.edu/ (last visited Aug. 2, 2007). Visit
NHGRI, ENCODE Overview, available at http://www.genome.gov/10005107 (last visited May 4, 2007). Professor
Bartha Knoppers addresses the importance of population genetics as a means to make medical sense out of the map
of the human genome in Biobanking: International Norms, 33 J. L. MED. & ETHICS 7, 7-12 (2005); Bartha Maria
Knoppers, Overview of Law and Policy Challenges, 66 LA. L. REV. 21, 21-31 (2005). For general discussion of
genetic science and medicine in the aftermath of HGP, see generally JAMES D. WATSON, DNA: THE SECRET OF LIFE
(Alfred A. Knopf ed., 2003); THE GENOMIC REVOLUTION: UNVEILING THE UNITY OF LIFE (Michael Yudell & Robert
DeSalle eds., 2002) (concluding, "The knowledge gained [from HGP] could cure cancer, prevent heart disease, and
feed millions. At the same time, its improper use can discriminate, stigmatize, and cheapen life through frivolous
enhancement technologies."); Allen Guttmacher & Francis Collins, Welcome to the Genomic Era, 349 NEW ENG. J.
MED. 996-98 (2004), available at www.nejm.org (last visited Aug. 3, 2007); Climbing the Helical Staircase: A
Survey of Biotechnology, THE ECONOMIST, Mar. 29, 2003, at 1-24.

7

presents a hypothetical case study illustrating the scientific complications and potential group
and social benefits of population genetics. This case study was selected to the side of the issue
of the race controversy intentionally with three primary objectives: to focus on population
genetics in the context of ongoing biomedical science and explain science fundamentals; to
emphasize that groups organized by genetic disease, often seen as a preferable alternative, may
in fact be no more homogenous than groups organized by race and ethnicity, even less so, while
still serving as a valuable research resource; and to demonstrate that responsible biobanking may
be beneficial on multiple levels regardless of the group collection criteria. The case study
illustrates the pervasive disconnect between phenotype (physical characteristics) and genetics
even in a group defined by a somewhat rare genetic disease; the bioethics benefits and
pragmatism of working with any population on its own social and cultural terms; the potential
control exercised by and benefits to the group under study; and the potential scientific and
medical returns, which tend to transcend a group under study given the youth and genetics
sameness of the human species. The overarching message is that responsible biobanking within
any population enables research to move forward and may contribute tremendously to human
health in sometimes very unpredictable ways.
The focus of Part V shifts back to race and ethnicity and proposes that recognition of and
responsiveness to social constructs of race and ethnicity promotes the fundamental principles of
contemporary bioethics. This argument rests heavily on the observations that, first, race and
ethnicity are as real socially as genetics is scientifically. Second, these concepts, albeit social
and cultural constructs,16 have influenced, and in future generations will continue to influence,

16

See supra note 1 and accompanying text.

8

how people perceive themselves, whom they marry, their lifestyles, and how others perceive and
interact with them—in other words, myriad environmental and genetic influences.17
The article concludes that, while the dangers of exploitation and discrimination must be
underscored,18 the concepts of race and ethnicity should be fully recognized and responded to in
a receptive manner by the scientific communities. In fact, the article proposes that applied
bioethics and scientific pragmatism favor recognizing race and ethnicity19 as a preferred
methodology for population genetics because this approach is most sensitive to selfidentification by study subjects, communication with individual members of groups under study,
realization of individual consent, recognition and assessment of group impact, and the
development and realization of group consent in contemporary population genetics.20 In
addition, the article illustrates that “shoddy science” arguments against race-based genetics
research are actually consistent with the goal of its advancement in a bioethics-sensitive manner,
especially given the intensity of the surrounding debate and the critiquing environment that
encompasses this research. As explained in the article, in the event the critics are correct, the
17

“Beliefs about race, and behaviors that construct race, can be derived and analyzed using research methods from
history, law, anthropology, sociology and psychology.” Ossorrio, About Face, supra note 2, at 278. See generally
Race, Ethnicity, and Genetics Working Group, The Use of Racial, Ethnic, and Ancestral Categories in Human
Genetics Research, 77 AM. J. HUMAN GENETICS 519-32 (2005); KITCHER, supra note 8. See infra notes 157-160
and accompanying text. Even Professors Lillquist and Sullivan, among the sharpest law academia critics of racebased research, have acknowledged that “it has been relatively safe, at least in the United States, to assume that race
correlated with ancestry, although even in the United States the admixture of races is significant.” Lillquist &
Sullivan, supra note 9, at 544.
18

Troy Duster, Race and Reification in Science, 307 SCI. 1050, 1050 (2005); Hoffman, Unraveled, supra note 6, at
420-27; Michael J. Malinowski, Choosing the Genetic Makeup of Our Children: Our Eugenics Past—Present, and
Future?, 36 CONN. L. REV. 125, 172–97 (2003).

19
It is important to note the distinctions and connections among race, ethnicity, and ancestry, which have been
explained fully in both the science and law literature. See, e.g., Race, Ethnicity, and Genetics Working Group, The
Use of Race, Ethnic, and Ancestral Categories in Human Genetics Research, 77 AM. J. HUM. GEN. 519-32 (2005);
Lillquist & Sullivan, Use of Race, supra note 6, at 536-537. See generally KITCHER, supra note 8.
20
See generally Henry Greely, Population Participation and Other Factors that Impact the Compilation and the
Utility of Resulting Databases, 66 LA L. REV. 79 (2005). See also Bartha Maria Knoppers, Biobanking:
International Norms, 33 J. L. MED. & ETHICS 7, 10 (2005). See infra notes 177-198 and accompanying text.

9

advancement of race-based genetics will further establish the genetic fallacy of these groupings,
create an opportunity for groups organized by race and ethnicity to participate in the genomics
revolution on favorable terms as determined by them, and may result in genetic medicine
applications that benefit the groups understudy directly and that transcend these groups and
benefit the entire human species. This research also would advance fields of science such as
epigenetics: the study of heritable changes in gene function that occur without a change in DNA,
which some are referring to as the “other human genome.”21 Epigenetics is grounded in
appreciation for the extent to which environment and lifestyle choices impact gene expression,
for example, the environmental influences that often cause identical twins to become very
different people as they progress through life.22

II. Measuring the Genetic Reality of Race, Then and Now
The present natural science debate over race-based genetics research is the progeny of
another started nearly half a century ago23—one deeply influenced by the experience of grossly
commingling life science in genetics and social science in eugenics at the turn of the Twentieth
Century through the era of Nazi Medicine,24 all in addition to the U.S. legacy of discrimination
based upon race and ethnicity.25 A particular field of science has driven each era in the debate,

21
See generally DAVID C. ALLIS, THOMAS JENUWEIN, & DANNY REINBERG, EPIGENETICS (2007); Adrian Bird,
Perceptions of Epigenetics, NATURE, May 24, 2007, vol. 447, no. 7143 (May 24, 2007); JAMES A. GOODRICH,
BINDING AND KINETICS FOR MOLECULAR BIOLOGISTS (2007); ERIC H. DAVISON, THE REGULATORY GENOME: GENE
REGULATORY NETWORKS IN DEVELOPMENT AND EVOLUTION (2006); Epigenetics, SCIENCE, Aug. 10, 2001 (Spec.
Iss.); visit Epigenetics, http://www.pbs.org/wgbh/nova/sciencenow/3411/02.html.
22

See generally supra note 21.

23

See generally infra Part II.A.

24

Malinowski, Choosing, supra note 18, at nn. 25-67 and accompanying text.

25
See generally, Ian F. Haney Lopez, “A Nation of Minorities”: Race, Ethnicity, and Reactionary Colorblindness,
59 STAN. L. REV. 985 (2007); Daniel J. Sharfstein, Crossing the Color Line: Racial Migration and the One-Drop
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which has been cumulative and has grown more complicated over time. The intensity and
richness of the present debate, including the genetic science community’s response to Dr.
Watson’s recent comments,26 is the greatest assurance that race-based research and its outcomes
will be scrutinized thoroughly—both scientifically and ethically.

A. Genetic Anthropology and Evolutionary Biology
The original post-World War II discourse over race-based genetics inspired several fields,
including genetic anthropology27 and molecular evolution,28 which emerged in the 1960s and
grew significantly throughout the 1970s.29 By the 1980s, the debate had been largely quieted by
an impressive body of scholarship that established persuasively that race is a social construct, not
a genetic reality. Much of this scholarship is attributable to: Luca Cavalli-Sforza from Stanford
University, widely recognized as the father of genetic anthropology;30 Marcus Feldman, a
Stanford colleague and collaborator of Professor Cavalli-Sforza, whose work centered on the

Rule, 1600-1860, 91 MINN. L. REV. 592 (2007); KENNETH B. CLARK, DARK GHETTO: DILEMMAS OF SOCIAL POWER
(1965).
26

See supra notes 1-3 and accompanying text.

27

See infra note 20.

28

See infra note 22.

29
This debate was a response to the jolt in understanding of human genetics following the discovery of the double
helix structure of DNA by Dr. James Watson and Francis Crick in 1953. See generally JAMES WATSON, THE
DOUBLE HELIX (1968).
30
Professor Cavalli-Sforza’s vast body of related scholarship before, during, and subsequent to the 1980s includes
LUCA L. CAVALLI-SFORZA & W. BODMER, THE GENETICS OF HUMAN POPULATIONS (1999); LUCA L. CAVALLISFORZA, P. MENOZZI, AND A. PIAZZA, THE HISTORY AND GEOGRAPHY OF HUMAN GENES (1994); Luca L CavalliSforza, The Human Genome Diversity Project: Past, Present and Future, 4 NAT REV GENET 333-40 (2005); Luca L.
Cavalli-Sforza, Studying Diversity, 6 EMBO REP 713 (2005); Luca L. Cavalli-Sforza, Man and the Diversity of His
Genome. An Extraordinary Phase in the History of Population Genetics, 46 PATHOL BIOL (PARIS) 98-102 (1998);
Luca L. Cavalli-Sforza, The DNA Revolution in Population Genetics, 16 TRENDS GENET 60-5 (1998); Luca L.
Cavalli-Sforza, P. Menozzi, A. Piazza, Demic Expansions and Human Evolution, 259 SCIENCE 639-46 (1993).
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genetic evolution of complex systems;31 and zoologist Richard Lewontin from Harvard
University, who established the mathematical basis of population genetics and is often credited
with founding the field of molecular evolution.32 These scientists demonstrated that there was
greater genetic variation within the racial groups they studied than between them, meaning that
grouping based upon genetic commonality crossed the racial lines they tested. As stated by
Professor Lewontin, “For the vast majority of human genetic variations, classical racial
categories as defined by a combination of geography, skin color, nose and hair shape, and an
occasional blood type or selected microsatellites make no useful prediction of genetic
differences.”33 Consequently, during the last quarter of the last century, the natural science
community, including the genetics community, largely abandoned race and ethnicity as
biological categories.

B. The Social Scientists
Then, during the 1990s, the social science community reinvigorated the debate. The late
Richard Herrnstein and Charles Murray published The Bell Curve, in which they attempted to
measure the role intelligence plays in shaping social and economic differences between ethnic
groups in America. 34 They claimed that intelligence is genetically inheritable in a predictable

31
See, e.g., LUCA L. CAVALLI-SFORZA & MARCUS W. FELDMAN, CULTURAL TRANSMISSION AND EVOLUTION
(1981); Luca L. Cavalli-Sforza & Marcus W. Feldman, The Application of Molecular Genetic Approaches to the
Study of Human Evolution, 33 NAT GENET (SUPP.) 266-75 (2003).
32

See RICHARD C. LEWONTIN, THE TRIPLE HELIX: GENE, ORGANISM, AND ENVIRONMENT (2000); RICHARD C
LEWONTIN, BIOLOGY AS IDEOLOGY: THE DOCTRINE OF DNA (1993). For a recent statement about race and genetics
by Professor Lewontin, see Richard Lewontin, Confusions About Human Races, Apr. 20, 2005, posted on Is Race
Real?, A Web Forum Organized by the Social Science Research Council, available at
http://raceandgenomics.ssrc.org/Lewontin/ (last visited June 6, 2007).
33

Confusions, supra note 32.

34

See generally RICHARD HERNSTEIN & CHARLES MURRAY, THE BELL CURVE (1994).
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manner, which they attempted to substantiate with research that relied on IQ scores.35 Hernstein
and Murray concluded that African Americans are less intelligent than Whites based upon a
fifteen to sixteen point differential on IQ tests:
Despite the forbidding air that envelops the topic, ethnic differences in cognitive
ability are neither surprising nor in doubt. Large human populations differ in
many ways, both cultural and biological. It is not surprising that they might differ
at least slightly in their cognitive characteristics. That they do is confirmed by the
data on ethnic differences in cognitive ability from around the world … The
difference in test scores between African-Americans and European-Americans as
measured in dozens of reputable studies has converged on approximately a one
standard deviation difference for several decades. Translated into centiles, this
means that the average white person tests higher than about 84 percent of the
population of blacks and that the average black person tests higher than about 16
percent of the population of whites.36
Critics questioned the objectivity of IQ tests and attributed economic disparities to less
quantifiable data, such as social circumstances.37
A year later, Michael Levin published Why Race Matters: Race Differences and What
They Mean, in which he too claimed that African-Americans are less intelligent than whites,38

35

See generally id.

36

Id. at 269.

37

See, e.g., CLAUDE S. FISCHER ET AL., INEQUALITY BY DESIGN: CRACKING THE BELL CURVE MYTH (1996); THE
BELL CURVE WARS: RACE, INTELLIGENCE, AND THE FUTURE OF America (Steven Fraser ed., 1995).
38
See generally MICHAEL LEVIN, WHY RACE MATTERS: RACE DIFFERENCES AND WHAT THEY MEAN (1997). In
Levin’s own words,
[I]t always is assumed that Blacks are on average as intelligent as whites and as capable of passing
any fair test in proportionate numbers. But there is now quite solid evidence that this assumption is
not correct; the average black is significantly less intelligent than the average white. Therefore, the
only adjustments in educational measures that will allow blacks their due number of successes
amount to making course-work and tests easier and easier, and this is what has been going on for
over thirty years. Conversely, if standards are going to be raised, cultural literacy reasserted and
college education given its old depth and focus, the American policy will have to reconcile itself
to an embarrassing failure rate for blacks. It has been amply confirmed over the last several
decades that, on average, blacks are significantly less intelligent than whites. The black mean IQ is
slightly more than one standard deviation below the white mean. In more familiar terms, that
amounts to a difference of more than 15 points of IQ as measured by such standard tests as the
Wechsler Adult Intelligence Scale.
Id. at __.
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and then went much further. He concluded that African Americans are more aggressive,
assertive, impulsive, and suffer from “an absence of conscience.”39 As with the work of
Hernstein and Murray, Levin’s work was heavily criticized and entirely dismissed by many.40

C. The Surge in Population Genetics
The turn of the Millennium has brought a surge in race-based genetics research41 and
genotype-phenotype connections associated with race.42 Additionally, considerable ancestrybased research, though distinguishable,43 raises implications that are spilling into the racegenetics controversy.44 The increase in race-based genetics research is attributable to completion

39

Id. at 213, 322.

40

See generally JOSEPH L. GRAVES, JR., THE EMPEROR'S NEW CLOTHES: BIOLOGICAL THEORIES OF RACE AT THE
MILLENNIUM (2001). According to Professor Graves, both The Bell Curve and Why Race Matters were funded in
part by the Pioneer Fund, "The purpose of [which] was to demonstrate the genetic inferiority of blacks." Id. at 154.
41

See Neil Risch, Dissecting Racial and Ethnic Differences, 354 NEW ENG. J. MED. 408 (2006). See generally
supra note 5. “There is a growing movement in medical genetics research and practice to develop, implement, and
promote a model of race-based medicine.” C. Condit & B. Bates, How Lay People Respond to Messages About
Genetics, Health, and Race, 68 CLINICAL GENETICS 97 (2005).
42

See, e.g., C. A. Haiman, D. O. Stram, L. R. Wilkens, et al., Ethnic and Racial Differences in the Smoking-Related
Risk of Lung Cancer, 354 N ENGL J. MED 333-42 (2006) ; X. Zhu, A. Luke, R. S. Cooper, et al., Admixture Mapping
for Hypertension Loci With Genome-Scan Markers, 37 NATURE GENETICS 177-81 (2005); Richard S. Cooper, et al.,
An International Comparative Study of Blood Pressure in Populations of European vs. African Descent, 3 BMC
MED. 2 (2005); M. Nakajima, T. Yokoi, Interindividual Variability in Nicotine Metabolism: C-oxidation and
Glucuronidation, 20 DRUG METAB PHARMACOKINET 227-35 (2005); G. E. Swan, N. L. Benowitz, C. N. Lessov, P.
Jacob III, R. F. Tyndale, K. Wilhelmsen, Nicotine Metabolism: the Impact of CYP2A6 on Estimates of Additive
Genetic Influence, 15 PHARMACOGENET GENOMICS 115-25 (2005); N. Kaniwa, K. Kurose, H. Jinno, et al., Racial
Variability in Haplotype Frequencies of UGT1A1 and Glucuronidation Activity of a Novel Single Nucleotide
Polymorphism 686C> T (P229L) Found in an African-American, 33 DRUG METAB DISPOS 458-65 (2005); F.
Innocenti, S. D. Undevia, L. Iyer, et al., Genetic Variants in the UDP-Glucuronosyltransferase 1A1 Gene Predict
the Risk of Severe Neutropenia of Irinotecan, 22 J CLIN ONCOL 1382-8 (2004); N. L. Benowitz, E. J. Perez-Stable,
B. Herrera, P. Jacob III, Slower Metabolism and Reduced Intake of Nicotine from Cigarette Smoking in ChineseAmericans, 94 J NATL CANCER INST 108-15 (2002); Neal L. Benowitz et al, Ethnic Differences in NGlucuronidation of Nicotine and Cotinine, 291 J. PHARMACOLOGY & EXPERIMENTAL THERAPEUTICS 1196 (1999);
Daniel L. Dries et al., Racial Differences in the Outcome of Left Ventricular Dysfunction, 340 NEW ENG. J. MED.
609, 616 (1999); Michael J. Klag, et al, The Association of Skin Color With Blood Pressure in U.S. Blacks With Low
Socioeconomic Status, 265 J. AM. MED. ASS’N 599 (1991). For an insightful discussion of the clinical utility of race
and ethnicity in medicine, see generally Cohn, supra note 9.
43

For an excellent explanation of this distinction, see Ossorio, About Face, supra note 2, at 279-284.

44

See Lillquist & Sullivan, Regulation, supra note 65, at 545-546. Note that NIH’s National Human Genome
Research Institute (“NHGRI”) has distinguished ancestry from race and ethnicity in its International HapMap
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of the map of the human genome in 2001,45 the bioinformatics capabilities that enabled that
accomplishment and which continue to expand by multiples, 46 and the broader understanding
about human genetics that has followed. 47 Completion of the map of the human genome was
both a remarkable accomplishment and humbling. As former President Bill Clinton observed at
the time of its announcement:
We are here to celebrate the completion of the first survey of the entire human
genome. Without a doubt, this is the most important, most wondrous map ever
produced by humankind.
More than 1,000 researchers across six nations have revealed nearly all 3 billion
letters of our miraculous genetic code. I congratulate all of you on this stunning
and humbling achievement.
Today's announcement represents more than just an epic-making triumph of
science and reason. After all, when Galileo discovered he could use the tools of
mathematics and mechanics to understand the motion of celestial bodies, he felt,
in the words of one eminent researcher, "that he had learned the language in
which God created the universe."
Project (“HMP”). See The International Haplotype Mapping Project, available at http://www.hapmap.org/ (last
visited July 12, 2007). Nevertheless, HMP has raised many social, ethical and legal concerns about population
genetics research that can be associated with race and ethnicity. See generally Ellen Wright Clayton, Implications
for Existing Law/Regulations, 66 LA. L. REV. (Special Issue) 125, 129 (2005); Pilar N. Ossorio, Race, Genetic
Variation and the Haplotype Mapping Project, 66 LA. L. REV. (Special Issue) 131 (2005).
45
See generally 291 SCIENCE 1145 (Feb. 16, 2001) (issue entitled "The Human Genome"); 409 NATURE 745
(Feb. 15, 2001) (issue dedicated to the release of a draft map of the human genome). Timely information about the
genomics revolution may be obtained from the National Human Genome Research Institute (NHGRI), available at
http://www.nhgri.nih.gov (last visited May 24, 2007).
46

See generally ESSENTIALS OF GENOMICS AND BIOINFORMATICS (C.W. Sensen ed., 2005); Robert Wells,
Intellectual Property/Ownership Interests, 66 LA L. REV. 69, 70 (2006). As explained previously,
Even before completion of the map of the human genome, the biomedical research community
began employing bioinformatics to undertake a challenge dimensions greater than the basic
genome mapping: translating this rambling string of letters that constitute the genome map into
medical meaning. Consider that even just single-letter changes may cause variance in
responsiveness to pharmaceuticals and susceptibility to diseases. The science community has
been identifying these genetic idiosyncracies that appear in the human population with statistically
significant regularity, known as SNPs, and compiling massive databases.
Michael J. Malinowski, Technology Transfer in Biobanking: Credits, Debits, and Population Health Futures, 33 L.
MED & ETHICS 54, 56 (2005).
47
See generally PAUL MARTIN & MICHAEL MORRISON; REALIZING THE POTENTIAL OF GENOMIC MEDICINE (2006).
Most notably, we came to understand that all human diversity is attributable to just 25,000 or less active genes. See
J. Michael McGinnis, Population Health and the Influence of Medical and Scientific Advances, 66 LA. L. REV. 9, 10
(2005).
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Today, we are learning the language in which God created life.
Genome science will have a real impact on all our lives—and even more, on the
lives of our children. It will revolutionize the diagnosis, prevention and treatment
of most, if not all, human diseases.48
The map introduced perspective. Rather than the 100,000 or so genes expected by most
at the outset of HGP, a mere 25,000 or fewer genes are responsible for all human diversity.49
“Yet, one need only ride the New York City subway a few stops or people watch in Times
Square to witness just how diverse we are, especially for such a young species. So, how do we
resolve our genetic sameness with tangible human diversity?”50 Genes multitask exponentially
more than anticipated. Two unrelated human beings are separated by an estimated 3,000,000
distinct DNA variants.51 With the map of the human genome in hand, those engaged in
biopharmaceutical R&D and genetic medicine stepped into a universe of added complexity.
Perspective has shifted: The scientific communities now have a significantly heightened
appreciation for the dynamism of genetics, the intricacies of genetic expression, and the
significance of interactions between genetics and environmental influences.52 This shift is
reflected in the emergence of epigenetics, which centers on environmental influences on, not
changes to, DNA that become heritable changes in gene function.53

48
49

Visit http://www.genome.gov/10001356 (last visited May 16, 2007).
McGinnis, Influence, supra note 38, at 10.

50
Malinowski, Futures, supra note 46, at 56. Henry T. Greely, Daniel P. Riordan, Nanibaa' A. Garrison, Joanna L.
Mountain, Family Ties; The Use of DNA Offender Databases to Catch Offenders’ Kin, 34 J.L. MED. & Ethics 248,
249 (2006).
51
See SNP Consortium Ltd., Single Nucleotide Polymorphisms for Biomedical Research, available at
http://snp.cshl.org (last visited May 12, 2007). See also L. Brooks and M. Guyer, National Human Genome
Research Institute (HGRI), Resource for Studying Human Genetic Variation (March 1998), available at
www.georgetown.edu/research/nrcbl/nbac/transcripts/mar98/hbmr_spkrs.htm (last visited Feb. 18, 2005).
52
Cf. Richard S. Cooper & Bruce M. Psaty, Genomics and Medicine: Distraction, Incremental Progress, or the
Dawn of a New Age?, 138 ANNALS INTERNAL MED. 576 (2003).
53

See supra notes 21-22 and accompanying text.
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As overwhelming as this shift in scale is, bioinformatics,54 the same technology that
enabled completion of the map of the human genome is enabling scientists to make medical
sense of it. Rather than working only at the gene or even protein level, scientists are reaching
down further to study variations in single nucleotide bases and their impact on phenotype
(physical characteristics), which are known as single nucleotide polymorphisms (“SNPs”).55
Single letter variants can be subtle—for example, a trigger that causes a gene to not make a
needed protein that, through an intricate pathway of interactions, results in nonresponsiveness or
over-responsiveness to a particular pharmaceutical. They also can be extreme, such as the
deviation of one nucleotide that triggers Tay Sachs and takes a child’s life.56 Approximately two
million of these subtle genetic variations with medical meaning have been identified—most a
byproduct of the ongoing expenditure of tens of billions of dollars annually on
biopharmaceutical research and development (“R&D”).57 Clusters of these variations inherited
together are referred to as haplotypes.58

54

Bioinformatics is the combination of biology and information technology. See generally, ESSENTIALS, supra note
46; Wells, Ownership, supra note 46.
55
SNPs are individual sites of genomic variation that occur with a frequency of at least 1% in the human population.
See The International SNP Map Working Group, A Map of Human Genome Sequence Variation Containing 1.42
million Single Nucleotide Polymorphisms, 409 NATURE 928-933 (2001). For information about SNPs, visit the site
of The SNP Consortium Ltd., supra note 44. See generally Helen Berman & Rochelle Dreyfuss, Reflections on the
Science and Law of Structural Biology, Genomics, and Drug Development, 53 UCLA L. REV. 871, 882-883 (2006).
56

Tay-Sachs is caused by a recessive genetic allele, a genetic variation on chromosome 15. For information, visit
the Mayo Clinic internet site at http://www.mayoclinic.org/tay-sachs-disease/genetesting.html. More information is
available via the National Tay-Sachs and Allied Disease Association, available at http://www.ntsad.org (last visited
May 16, 2007).
57

Some of these commercial entities have joined a collaboration, The SNPs Consortium Ltd., supra note 44, to put
SNPs into the public domain. This effort is complemented by another consortium, the Wellcome Trust, which has a
focus on structural genomics. See Wellcome Trust, Structural Genomics Consortium, http://
www.wellcome.ac.uk/doc_WTD003502.html (last visited Oct. 31, 2005). For information about biopharmaceutical
investment in drug research and development, visit the sites of the U.S. pharmaceutical trade organization,
Pharmaceutical Researchers and Manufacturers of American, www.phrma.org, and the U.S. biotechnology trade
organization, the Biotechnology Industry Organization, www.bio.org (last visited June 4, 2007).
58

See generally International HapMap Project, What is the HapMap?, http://
www.hapmap.org/whatishapmap.html.en (last visited Jan. 22, 2007).
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Today’s quest to find medical meaning in the genome has raised insatiable demand for
human biological samples and accompanying medical information.59 Appreciation for the scope
of the universe of human genetic subtleties made discernable by the map of the human genome
has expanded the scale of much genetics research from the study of families and disease groups
to the study of entire populations.60

III. The Ongoing Debate Over Race-Based Research
Though the genetics science community and its research is at the center of the ongoing
debate over race-based research, the social science and law communities also are actively
engaged—making the present debate full-bodied, interdisciplinary, sophisticated and
challenging.61 As Professor Wolf has observed, “A number of conflicting proposals have been
offered, some to discipline and improve the use of racial and ethnic categories, and some to
eliminate such categories. This is a debate affecting researchers, funders, journal editors,
research participants, and the broader community.”62

A. Opponents
Those in the scientific and medical communities opposed to research based on race and
ethnicity emphasize that these groupings are inconsistent with the scientific reality of human

59

See Paula W. Yoon, Risk Prediction for Common Diseases, 66 LA L. REV. 33, 40 (2005).

60

See generally Symposium: Regulation of Biobanks, 33 J. L. MED. & ETHICS 1-188 (Mark Rothstein & Bartha
Knoppers eds., 2005); Populations and Genetics: Legal and Socio-Ethical Perspectives (Ed. Bartha Maria Knoppers,
2003); Lorraine Sheremeta & Bartha Maria Knoppers, Beyond the Rhetoric: Population Genetics and BenefitSharing, 11 HEALTH L.J. 89, 90 (2003) (listing privacy as one of many concerns raised in present DNA testing).
61

Professor Troy Duster, a sociologist, is an active participant. See infra note 58-59. Among law academics,
Professors Sharona Hoffman, Eric Lillquist, Charles Sullivan, and Jonathan Kahn entered the debate early and have
been fully engaged, and Professor Susan Wolf hosted a major symposium in the fall of 2006 which generated an
issue of the Journal of Law, Medicine and Ethics dedicated to the topic. See supra note 9.
62

Wolf, Debating Use, supra note 51, at 483.
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genetics.63 They draw from the ample body of literature by Professors Cavalli-Sforza, Lewontin
and their contemporaries, and also reference recent findings which bolster the argument that race
and ethnicity are more social constructs than genetic realities.64 Opponents assert that a
preferred methodology for population genetics is research centered on diseases or at least
specific and more reliable genetic particulars.65 They argue this approach will help avoid
wasting resources, forcing outcomes, and chancing the affirmation of racial and ethnic groupings
and social stereotypes. According to bioethicist and Ph.D. scientist Mildred Cho, the race and
ethnicity categories are unworkable: “Because social perceptions of the meaning of race and
ethnicity are extremely fluid, basing research findings on these categories or applying scientific
findings based on perceived race or ethnicity is fraught with problems. Thus, attempts to “`better
define [the racial and ethnic] structure [of drug response]’ will be futile.”66
Sociologist Troy Duster and many other opponents raise concerns about biologic
determinism, meaning that genetic protocols crafted around race and ethnicity will become selffulfilling prophecies. They emphasize the genetic commonality in any group due to the youth of

63
See, e.g., M. V. Osier, A.J. Pakstis, H. Soodyall, D. Comas, D. Goldman, K. Odunsi, F. Okonofua, J. Parnas, L.
Schulz, J. Bertranpetit, B. Bonne-Tamir, R.-B. Lu, J.R. Kidd, and K.K. Kidd, A global Perspective on Genetic
Variation at the ADH Genes Reveals Unusual Patterns of Linkage Disequilibrium and Diversity, 71 AM. J. HUM.
GEN. 84, 84-99 (2002); N.A. Rosenberg, J.K. Pritchard, J.L. Weber, H.M. Cann, K.K. Kidd, L.A. Zhivotovsky, &
M.W. Feldman, Genetic Structure of Human Populations, 298 SCIENCE 2381-2385 (2002). J.R. Kidd, A.J. Pakstis,
H. Zhao, R.-B. Lu, F.E. Okonofua, A. Odunsi, E. Grigorenko, B. Bonne-Tamir, J. Friedlaender, L.O. Schulz, J.
Parnas, & K.K. Kidd, Haplotypes qnd Linkage Disequilibrium at the Phenylalanine Hydroxylase Locus (PAH) in a
Global Representation of Populations, 66 AM. J. HUM. GEN. 1882-1899 (2000).
64

See generally Ossorio, About Face, supra note 2; Ossorio, Genetic Variation, supra note 37.

65
See generally Ossorio, About Face, supra note 2; Gegg Bloche, Market Incentives and Regulatory Constraints:
Racial and Ethnic Categories in Pharmaceutical Research, 34 J. L., Med. & Ethics 555-558 (2006); Raj Bhopal &
L. Donaldson, White, European, Western, Caucasian, or What?: Inappropriate Labeling in Research on Race,
Ethnicity, and Health, 88 AM. J. OF PUB. H. 88, 1303-07 (1998); Foster, Analyzing Race, supra note 6; Margaret A.
Winker, Race and Ethnicity in Medical Research: Requirements Meet Reality, 34 J. L. MED. & ETHICS 520 (2006).
66
Mildred K. Cho, Racial and Ethnic Categories in Biomedical Research: There is No Baby in the Bathwater, 34
J.L. MED. & ETHICS 497, 499 (2006), quoting Cohn, supra note 9.
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the human species and its overwhelming genetic sameness.67 Professor Duster also addresses the
broader social implications of underscoring lines traditionally drawn around groups based upon
race and ethnicity through genetics research protocols that suggest their validity. He warns that
singling out these groups further affirms prejudices and increases their vulnerability to
discrimination, exploitation, and health inequality.68 According to Professor Duster, 69 the
scientific community has shifted from “genetic sameness” as the mantra for mapping the human
genome to a mantra of “genetic differentiation” through ongoing efforts to make medical sense
out of the genome map, including population genetics,70 pharmacogenomics,71 and identification
of SNPs.72
A number of law academics have entered the debate and have argued against the
perpetuation of race in the biomedical context with cautions about the weighty social and legal
implications involved.73 In fact, there is a discernible majority opinion among law academics

67

See generally Troy Duster, Lessons from History: Why Race and Ethnicity Have Played a Major Role in
Biomedical Research, 34 J.L. MED. & ETHICS 487 (2006); Prof. Troy Duster, Dinner Presentation, "The
Globalization of Pharmaceutical Development: Race, Markets and Ethics" (Mar. 16, 2006, Santa Clara College of
Law) (addressing the "shift from genetic sameness to individuality" pre- and post-HGP); Troy Duster, Race and
Reification in Science, 307 SCI. 1050, 1050 (2005); Risch, Dissecting, supra note 8.
68
Duster, Dinner Presentation, supra note 67. See generally Duster, Reification, supra note 67; Duster, Lessons,
supra note 67. Sociologist Rose Brewer recently raised many similar concerns. See generally Rose M. Brewer,
Thinking Critically About Race and Genetics, 34 J.L. MED. & ETHICS 513 (2006).
69

Duster, Dinner Presentation, supra note 67.
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See supra notes 12, 32-50 and accompanying text.
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Complementary fields are pharmacogenomics, which is research centered on the expression of alleles shared by
groups, and pharmacogenetics, the tailoring of health care and biopharmaceuticals to individual genetic profiles. See
generally Michael J. Malinowski, Law, Policy, and Market Implications of Genetic Profiling in Drug Development,
2 H. J. OF HEALTH LAW & POL'Y 31-63, 31-43 (2003); L. Noah, The Coming Pharmacogneomics Revolution:
Tailoring Drugs to Fit Patients' Genetic Profiles, 43 JURIMETRICS 1, 4-11 (2002).
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See supra notes 45-48 and accompanying text.
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See supra note 9 and accompanying text.
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that race-based genomics research is undesirable on multiple levels and perhaps even illegal.74
The literature includes articles by Professors Erik Lillquist and Charles Sullivan,75 Professor
Sharona Hoffman,76 Professor Jonathon Kahn,77 and a University of Minnesota symposium
chaired by Professor Wolf which includes an article by Professor Dorothy Roberts.78
Proposals have been made to distinguish basic, clinical, epidemiological, and other forms
of research, and to introduce legal restraints on the use of race and ethnicity in a manner tailored
to each research specialty.79 The general consensus among law opponents is that use of race and
ethnicity in biomedical research always warrants caution and legal restraints, but there is a
continuum: use of race in clinical research is least acceptable; use in epidemiological research,
such as research on the correlation between race and health disparities, is most acceptable; and
other types of research place between the two.80 Also, the general consensus is that the use of
race in research and medicine runs contrary to U.S. law and policy that broadly proscribes it.
Professors Lillquist and Sullivan conclude that the use of race in research and medicine should
be severely circumscribed, if not prohibited almost entirely.81 Their proposed standard for using

74

See id.

75
See generally Lillquist & Sullivan, Regulations, supra note 9. See also Lillquist & Sullivan, Racial Profiling,
supra note 9, at 442.
76

See Hoffman, Unraveled, supra note 9, at 395-456.

77

See generally Kahn, Racing Patent, supra note 9; Kahn, Racial Categories, supra note 9, at 25.

78

See generally Symposium, The Responsible Use of Racial and Ethnic Categories in Biomedical Research: Where
Do We Go From Here?, 34 J.L. MED. & ETHICS 483 (fall 2006) (published outcomes of live symposium at Univ. of
Minnesota); Roberts, Legal Constraints, supra note 6. Many of the contributors to this symposium were trained in
disciplines outside of law and approached the topic accordingly. See generally id. For citations to the other
symposium pieces, see supra note 0.
79

See Lillquist & Sullivan, Regulation, supra note 9, at 543-547.
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Id. at 546.
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See generally Lillquist & Sullivan, Racial Profiling, supra note 9.
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race in medical treatment is extremely restrictive. They would require a scientific basis to
establish not simply that use of race is helpful in diagnosis and treatment, but that it is the best
known method at the time.82 Professor Hoffman declares that “‘race-based’ medicine is an
inappropriate and perilous approach”83 and proposes regulatory reforms to heavily restrain, if not
entirely eliminate, both race-based research and medicine.84 She proposes “attributes-based”
identification as a race-neutral alternative.85

82

Id. at 442.

83

Hoffman, Unraveled, supra note 9, at 397.

84

See generally id.

85

As Professor Hoffman explained,
[T]o the extent that a group-oriented approach is pursued, it should be attribute-based rather than
`race-based,’ and scientists should invest considerable effort in accurately identifying the attribute
or attributes at issue. . . . The variables that might be relevant for a particular procedure or therapy
could include socioeconomic status, diet, exercise, stress level, exposure to environmental toxins,
cultural and religious barriers to treatment compliance, specific genetic alterations that influence
disease course or disease vulnerability, and other factors.
Id. at 398.
NIH is considering adoption of Professor Hoffman’s attributes-based identification, at least according to a
NIH representative during the question and answer session following Professor Hoffman’s presentation at the 30th
Annual Health Law Teacher’s Conference in June 2006. Session on Race-Based Research, 30th Annual Health Law
Teachers Conference, University of Maryland School of Law, June 1-3, 2006 (sponsored by the American Society
of Law, Medicine, and Ethics; materials on file with author, including list of attendees). NIH regulations expressly
require inclusion of minority groups in clinical research. NIH Policy on Reporting Race and Ethnicity Data: Subjects
in Clinical Research, August 8, 2001, available at <http:// grants1.nih.gov/grants/guide/notice-files/NOT-OD-01053.html (last visited June 12, 2006); U.S. Department of Health and Human Services, "Policy Statement on
Inclusion of Race and Ethnicity in HHS Data Collection Activities" (1997), available at
http://aspe.os.dhhs.gov/datacncl/racerpt/appendg.htm (last visited June 28, 2006). Under these rules, applicants for
grant funding must measure and report the race and ethnic composition of their intended study population and
provide a rationale for subject selection, in part to ensure inclusion of non-White populations traditionally
understudied. National Institutes of Health, "Policy and Guidelines on the Inclusion of Women and Minorities as
Subjects in Clinical Research," last modified Oct. 11, 2001, available at http://
grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm (last visited Mar. 10, 2007).
Adoption of the attributes-based approach would introduce administrative and compliance complexity and
inconsistency in federal policy, as recognized by the Office of Management and Budget (“OMB”), which has
refused to stray from race and ethnicity classifications for these very reasons. Under OMB Directive 15, race and
ethnic classifications are used for administrative practicality, as when conducting the national census. Statistical
Directive No. 15: Race and Ethnic Standards for Federal Agencies and Administrative Reporting, 43 Fed. Reg.
19,269-70 (May 4, 1978) [hereinafter Statistical Directive 15]. The classifications also are used by government
entities in a range of programs that require consideration of race with the objective of bringing about inclusion
where there has been a legacy of the opposite, including in biomedical research. See, e.g., CDC, "Racial and Ethnic
Approaches to Community Health: Goals for 2010," available at http://www.cdc.gov/reach2010/goals.htm (last
visited July 12, 2007). In other words, race and ethnicity are recognized to include and counter a legacy of
exclusion and discrimination. Even Professor Dorothy Roberts who opposes the use of race and ethnicity in
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Collectively, law academics generally approach race-based research from U.S.
jurisprudence and public policy against discrimination and associated social and ethical
concerns.86 Their analysis of potential legal constraints on race-centered research begins with
restrictions on intentional disparate treatment based on race by government entities under the
Equal Protection Clause of the Fourteenth Amendment and the Due Process Clause of the Fifth
Amendment.87 They emphasize that government use of racial classifications triggers strict
scrutiny, but recognize that government actions, including programs thoughtfully crafted to
promote affirmative action, survive such scrutiny where there is a compelling government
interest and the use of race is narrowly tailored to promote that interest.88 They generally
concede that, under established jurisprudence, government sponsorship of responsible race-based
genetics research is likely to survive such challenges, though the present Court recently

biomedical research supports their use to study and eliminate disparities in access to health care and medical
treatment. See Roberts, Legal Constraints, supra note 9, at 532-533.
86

See, e.g. , Hoffman, Unraveled, supra note 9; Lillquist & Sullivan, Regulation, supra note 9.

See generally Grutter v. Bollinger, 539 U.S. 306 (2003) (holding that the Univ. of Mich. Law School
has a compelling interest in attaining a diverse student body and that its affirmative action
admissions program was narrowly tailored to serve that compelling interest). Presently there is
some uncertainty regarding permissible government action in the context of race integration, for the
Supreme Court revisited the 1954 Brown v. Board decision in cases heard December 2006, Parents
Involved in Community Schools v. Seattle School District No. 1, 551 U.S. __ , 127 S.Ct. 2738, 75 USLW
4577, 220 Ed. Law Rep. 84 (NO. 05-908, 05-915) (2007), and Meredith v. Jefferson County Board of Education,
127 S.Ct. 575 (Mem), 166 L.Ed.2d 407, 75 USLW 3247 (NO. 05-915) (2007). See Adam Liptak, Brown v.
Board of Education, Second Round, N.Y. TIMES, Dec. 10, 2006, at 3. The Court considered whether
school systems in Seattle, Washington, and Louisville, Kentucky, could take account of the races of
students to achieve racial balance even though some students might be denied access to schools of
choice due to race balance considerations. See id. The Supreme Court concluded that “The school
87

districts have not carried their heavy burden of showing that the interest they seek to achieve [, namely racial
diversification,] justifies the extreme means they have chosen—discriminating among individual students based
on race by relying upon racial classifications in making school assignments.” Seattle, supra, at Slip. Op. para. 2,
p. 2.
88

See Grutter, 539 U.S. at 306.
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questioned the Seattle and Kansas City school diversity policies and subjected them to further
inquiry. 89
Professors Hoffman, Lillquist, and Sullivan also look to statutory schemes that expand
protection against racial discrimination—namely section 1981,90 Title VI,91 and Title II of the
Civil Rights Act of 1964. 92 However, again, they concede the limited applicability of these
provisions to race-based research. First, as they address, while section 1981 reaches beyond
government actions to contracts between private individuals, its prohibition on discrimination in
contracts is limited to intentional disparate treatment.93 The reach of Title II is limited to
discrimination or segregation in places of public accommodation, and courts have limited the
reach of Title VII in the medical context.94 Although Title VII prohibits race discrimination in
federally funded programs,95 courts have held that doctors receiving Medicare funding are not
“programs” within the meaning of the statute.96 The case holdings suggest that medical research
also would be beyond the statute’s reach. Moreover, although Title VII allows private causes of
89
See Seattle School District No. 1, 551 U.S. at __, and supra note 77. Professors Lillquist and Sullivan have
recognized that “The legal constraints on the use of race in research are more limited than might be expected given
the strong ethical consensus against harmful use of racial categories. The three major sources of federal regulation,
the Equal Protection Clause and two federal statutory schemes, together leave large areas untouched.” Lillquist &
Sullivan, Legal Regulation, supra note 6, at 540. Presumably the Supreme Court’s Seattle decision underscores this
observation..
90

42 U.S.C. § 1981 (2000).

91

42 U.S.C. § 2000d (2000).

92

42 U.S.C. § 2000a (2000).

93

See Sullivan & Lillquist, Legal Regulation, supra note 9, at 540.

94

See Hoffman, Unraveled, supra note 9, at 429-430.

95
Title VII has been interpreted to prohibit both disparate treatment and disparate impact discrimination. See
Hoffman, Unraveled, supra note 6, at 441-442.
96
See, e.g., Vuciecevic v. MacNeal Mem'l Hosp., 572 F. Supp. 1424, 1430 (N.D. Ill. 1983). See generally Lillquist
& Sullivan, Racial Profiling, supra note 6, at 445. In 1966, the Health, Education and Welfare Department decided
to exempt physician Medicare participants from Title VII compliance. See id.

24

action for intentional discrimination, only the federal government can challenge policies on the
basis of disparate impact.97 Professors Lillquist and Sullivan also acknowledge that government
restraints on private undertakings are limited by commercial free speech.98

B.

Proponents
Contemporary biomedical research encompasses numerous methodologies centered on

the study of populations, with the size of study groups varying from local communities to cross
sections of the global human population.99 Those in the science and medical communities who
support race-based research generally accept that grouping the human species on a universal
level according to the greatest genetic common denominators would likely cut through our
socially drawn race and ethnicity lines.100 The research of Professors Cavalli-Svorza, Lewontin,
and their contemporaries is impressive and persuasive.101 However, proponents of race-based
genetics research also are receptive to the notion that clusters of genetic commonalities, acquired
through ancestry or shared environmental exposures (defined to fully encompass social
influences), may be more prevalent in racial and ethnic groups than in the general population.102
In other words, they work with the premise that (a) comprehensive human species challenges to
the genetic reality of race and (b) the utility of race and ethnicity in population genetics are not

97

Lillquist & Sullivan, Racial Profiling, supra note 9, at 447-448; Hoffman, Unraveled, supra note 9, at 441-442.

98

See Lillquist & Sullivan, Racial Profiling, supra note 9, at 448-450. See generally Wash. Legal Found. v.
Henney, 202 F.3d 331 (D.C. Cir. 2000) (declaring the marketing of pharmaceutical products commercial free speech
and limiting restrictions).
99

Foster, Analyzing Race, supra note 9, at 508.

100

The research and scholarship of Professors Cavalli-Sforza, Feldman, and Lewontin remain persuasive on this
point. See supra notes 30-33 and accompanying text.

101

See id.

102

See generally Cohn, Lessons, supra note 9; Bhopal, Responsible Use, supra note 9; Risch, Dissecting, supra note

8.
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necessarily mutually exclusive. Rather, they perceive them as distinguished by scope and
complementary—along the lines of the use of micro- and macroeconomics by economists.103
Supporters assert that, at least in some instances, research centered on racial and ethnic
groupings has the potential to be a population extension of classic family pedigree studies in
which research is conducted on a scale necessary to address the genetic intricacies we more fully
discern and appreciate post completion of the human genome map. 104 A crisp illustration is an
ongoing multiple sclerosis (MS) study carried out by the University of California at San
Francisco and Harvard University under the International Multiple Sclerosis Genetic Consortium
to identify genetic variants that account for the difference in the risk of developing MS between
Africans and Europeans.105 The scientists are scanning DNA from African American MS
patients for regions that have an unusually high proportion of European or African ancestry.106
Their hypothesis is that, as the occurrence of MS is much higher in people of European ancestry,
African Americans with MS have inherited a higher than average proportion of European

103

The basic distinction is that microeconomics is about how markets operate while macroeconomics is about how
economies function. See generally SILK ET AL., MAKING CAPITALISM WORK 175 (1996); DOUGLASS C. NORTH,
ECONOMIC PERFORMANCE THROUGH TIME, PRIZE LECTURE IN ECONOMIC SCIENCE IN MEMORY OF ALFRED NOBEL
(Dec. 9, 1993); PETER HOWITT, MACROECONOMICS: RELATIONS WITH MICROECONOMICS, IN 3 THE NEW PALGRAVE:
A DICTIONARY OF ECONOMICS 273-75 (John Eatwell et al. eds., 1989) (outlining the disjunction between micro and
macro economics).
104

Cf. Bhopal, Responsible Use, supra note 9, at 500.

105
Daar & Singer, Geographical Ancestry, supra note 8 (editorial surveys ongoing pharmacogenetics research
projects and identifies the potential benefits of this research for developing economies).

106

This project is using 'admixture mapping', a type of haplotype association mapping. See David Reich, Nick
Patterson, et al., Letters, A Whole-Genome Admixture Scan Finds a Candidate Locus for Multiple Sclerosis
Susceptibility, 37 NATURE 1113, 1113-1118 (Oct. 2005). For explanation and discussion of haplotype mapping, see
supra note 58 and infra notes 110-118 and accompanying text.
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chromosomal regions.107 The first part of this study already has brought science closer to
interesting candidate genes.108
Additional research results substantiate the scientific merit of this methodology: Race
and ethnicity-based genetics research is bestowing medical benefits to groups under study. A
notable example is identification of the genetic causes of adverse drug reactions (“ADRs”) to
some commonly prescribed medications disproportionately prevalent in patients of South Asian
descent, not a common focus group in biopharmaceutical research and development. The use of
oseltamivir, commonly known as Tamiflu and widely stockpiled for use in a possible avian
influenza pandemic, has been associated with neuropsychiatric disorders and severe skin
reactions primarily in patients of Japanese origin.109 ADRs from Tamiflu eventually were linked
to a genetic aberration present in a small percentage of persons with Japanese origin.110
Asian populations also have experienced a disproportionately high ADR incident rate—
ten percent—with rosuvastatin (commonly named Crestor), a routinely prescribed statin
inhibitor. The side-effects of muscular myopathy and rhabdomyolysis were observed during the
Phase IV (post marketing) clinical testing period. The severity of these ADRs prompted a drug
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Daar & Singer, Pharmacogenetics, supra note 8, at 242.

108

See generally Reich, et al., Whole-Genome Admixture, supra note 106.

109

See generally Li, et al, Nonsynonymous SNP, supra note 8.

110 This allele (genetic variation) is a nonsynonymous SNP (single nucleotide polymorphism) near the region of
DNA coding for the enzymatic active site of human cytosolic sialidase, a homologue of virus neuraminidase that is
the target of oseltamivir. This SNP, not observed in persons of European and African American descent, occurs in
9.29 percent of Asian populations. ADRs to oseltamivir in Asian populations have been associated with the
tendency of this SNP to reduce sialidase activity (Li et al., 2007). The governing theory is that its presence increases
the unintended binding affinity of human sialidase to oseltamivir carboxylate, the active form of oseltamivir, thus
reducing sialidase activity. In addition, this SNP itself results in an enzyme with an intrinsically lower sialidase
activity. Id.
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advisory memorandum from the FDA that specifically regulated the dosage of Crestor for
persons of Asian descent.111
These and other ADRs in populations associated with racial classifications have inspired
several countries with Asian populations, populations not traditionally a study focus for
biopharmaceutical R&D based in the U.S. and Europe, to unite and form The Pacific Pan-Asian
SNP Initiative (“Pan-Asian Initiative”).112 The Initiative, hosted by the Genome Institute of
Singapore, has brought scientists together to research the breadth of genetic diversity and the
extent of genetic similarity within Asian populations.113 This information will form the basis for
future studies in genomic medicine focused on Asian populations. Data from the Pan-Asian
study will provide a platform for researchers in Asia to study why some populations seem
predisposed to certain diseases, do not respond to certain drugs, or experience adverse drug
reactions.114 Participating countries with complementary population genetics programs of their
own include Japan,115 Taiwan,116 and China.117

111

FDA Public Health Advisory on Crestor (rosuvastatin) (2005).

112

See generally Daar & Singer, supra note 8.

113

See id.

114

See id.

115 Japan begain the BioBank Japan Project in 2003 with the goal of collecting DNA, serum samples, and clinical
information from 300,000 patients. Triendl, R. Japan Launches Controversial Biobank Project, 9 NAT MED. 982
(2003). Biobank Japan is focused on elucidation of ADRs associated with oncological chemotherapy. The overall
goal of the BioBank Japan Project is to achieve personalized patient dosing capabilities to maximize positive
responsiveness and avoid ADRs, See generally Y. Nakamura, The BioBank Japan Project, 5 CLIN. ADV’S IN
HEMATOLOGY & ONCOLOGY 696-697 (2007).
116 The Taiwan Biobank was inspired by identification of hereditary and external risk factors unique to the
Taiwanese. See generally Wu, Y.-R., Chen, C.-M., Chao, C.-Y., Ro, L.-S., Lyu, R.-K., Chang, K.-H., et al.,
Glucocerebrosidase Gene Mutation is a Risk Factor for Early Onset of Parkinson Disease Among Taiwanese, 78 J.
NEUROL NEUROSURG PSYCHIATRY 977-979 (2007). The purpose of Taiwan Biobank is to investigate the gene
factors behind common chronic diseases in Taiwan, such as cancer, high blood pressure, and diabetes, and the
interactions of genetic and external risk factors. See id. Early findings include identification of a mutation common
in a subsection of the Taiwanese population that predisposes such patients to early onset of Parkinson’s disease. See
id.
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These ADRs also have inspired the FDA to conduct pharmacogenomic studies that
require evaluation of toxicity in separate race-based groups. A recent example is FDA approval
of alosetron hydrochloride for irritable bowel syndrome—the drug Lotronex by
GlaxoSmithKline.118 After an initial approval through the FDA, the drug was voluntarily
withdrawn by GlaxoSmithKline because of ADRs.119 However, because of its efficacy,
Lotronex was re-approved by the FDA in 2002 with market restrictions.120 Currently,
GlaxoSmithKline is studying the relationship between adverse events and genetic profiles as part
of FDA-imposed post-marketing commitments.121
The FDA also has required race identification in clinical trial design. In 2003, the FDA
demanded greater scrutiny of data from subpopulations and required incorporation of racial
catagories specified by the Census Bureau to ensure consistent evaluation of drug safety profiles
across racial groups. Then, in 2005, the FDA issued its first approval of a “race-specific”

117 China has several biobanking initiatives underway that position the nation for leadership in pharmacogenomic
studies. See generally, Jiang, C., Thomas, G. N., Lam, T. H., Schooling, C. M., Zhang, W., Lao, X., et al., Cohort
Profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration, 35 INT. J.
EPIDEMIOL 844-852 (2006). The Guangzhou biobank (GBCS), for example, is a collaborative project between the
UK and China and focuses on older people aged at least 50 years in a mega-city of approximately 10 million. See
id. Of these, 6.4 million are permanent residents with locally registered households, and the remainder are mostly
migrants from other parts of the country. See id. Guangzhou, the provincial capital of Guangdong province in
southern China, is one of the most economically developed regions of China. See id. The overall study population
design calls for 30,000 participants who are evaluated regularly by the bank. See id. The elderly population in
Guanzhou is uniquely exposed to two unique macroenvironments. Prior to 1949, this was a rural region. See id.
After formation of the People’s Republic of China, the region was industrialized. See id. Thus, potential early
genetic cues may differ substantially between the elderly population that developed through adolescence prior to the
1949 transition. See id.
118

Webster, W., Martin, P., Lewis, G. & Smart, A., Integrating Pharmacogenetics Into Society: In Search of a
Model, 5 NATURE REV. GENET. 663–669 (2004).

119

See id

120

See id.

121

See id.
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therapy— a fixed-dose combination of isosorbide dinitrate and hydralazine, now known as
BiDil, NitroMed, for use in African Americans with heart failure. 122
These events culminated in a 2005 FDA recommendation to pharmaceutical companies
that they include racial and ethnic data in their safety assessment protocols. The FDA adopted
the “Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials,” originally
issued by the Office of Management and Budget (OMB).123 This Guidance advises
pharmaceutical companies how to incorporate race and ethnicity in a standardized fashion within
existing protocols for pharmaceutical safety assessment of drugs.124 Under OMB Directive 15,
race and ethnic classifications are used for administrative practicality, based on the definitions
provided in the United States Census (Statistical-Directive-15, 1978). 125 The classifications also
are used by government entities in a range of programs that require consideration of race with the
objective of achieving inclusion where there has been a legacy of the opposite, including in
biomedical research.126 Consequently, inclusion of race in pharmacogenomic safety assessment
profiles for new drug applications is an increasingly accepted practice in the United States.

Bibbins-Domingo, K., & Fernandez, A., BiDil for Heart Failure in Black Patients:
Implications of the U.S. Food and Drug Administration Approval, 146 Ann Intern Med. 52-56
2007. See also infra notes 144-150 and accompanying text. Originally, the FDA rejected the
drug because its efficacy in treating heart failure could not be demonstrated statistically in a
clinical trial in the general population Franciosa, J. A., Fixed Combination Isosorbide DinitrateHydralazine for Nitric-Oxide-Enhancing Therapy in Heart Failure, 7 EXPERT OPIN
PHARMACOTHERAPY 2521-2531 (2006). However, the results of a subsequent doubleblind,
randomized clinical trial in 1,050 self-identified African-American patients who had experienced
heart failure were impressive enough to compel the FDA’s race-specific approval. See id.
122

123

Finding-Solutions-to-Health-Disparities: Racial and Ethnic Approaches to Community Health (REACH) in the
U.S. (Oct. 11, 2007), available at http://www.cdc.gov/reach/reach_2010/index.htm.

124

Id.

125

Id.

126

Id.
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Supporters emphasize the jolt in the scale of genetics research post completion of the map

of the human genome in 2001 to a level of intricacy dimensions beyond the capabilities of
genetic science in the years before.127 Today, many scientists are working at the level of
alterations in single nucleotides (just one adenine, cytosine, quinine, or thymine nucleotide base
among an individual’s three billion base pairs), and some even are identifying hereditary genetic
differences through environmental exposures that occur without changes in DNA.128
These proponents point to the ample positive outcomes of race and ethnicity-based
research, including findings from research in Amish129 and Ashkenazi Jewish populations,130 and
the higher incidence of some diseases associated with specific racial and ethnic groups, such as
Tay Sachs in Ashkenazi Jews131 and cystic fibrosis in Caucasians with Northern European
ancestry.132 They assert that race and ethnicity should be accepted as a possible research variable
especially in light of how environmental factors interact with and influence genetics, the
influence of race and ethnicity on how we group ourselves socially, the impact of these

127

See supra notes 55-58 and accompanying text.

128

This field, epigenetics, is addressed supra notes 21, 22, 53, infra note 117, and in the accompanying text.

129
See, e.g., Robert Wells, Intellectual Property Ownership Issues, 66 LA. L. REV. 69, 74 (2005) (discussing
collaboration between Affymetrix and Amish populations to identify the gene responsible for Swyer Syndrome and
a gene responsible for a new form of sudden infant death syndrome).
130

See, e.g., S.V. Hodgson et al., Risk Factors for Detecting Germline BRCA1 and BRCA2 Founder Mutations in
Ashkenazi Jewish Women with Breast or Ovarian Cancer, 36 J. MED. GENETICS 369 (1999).

131

National Institute of Neurological Disorders and Stroke, available at
http://www.ninds.nih.gov/disorders/taysachs/taysachs.htm (last visited June 4, 2007).

132

National Heart Lung and Blood Institute, available at
http://www.nhlbi.nih.gov/health/dci/Diseases/cf/cf_risk.html (last visited June 9, 2007).
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groupings on environmental exposures, and the fact that race and ethnicity have influenced social
groupings for centuries. 133 As explained by some researchers:
For example, individuals living in sub-Saharan rural Africa have close to 100% of what
are called African alleles, whereas African Americans living in the United States show
about 26% Caucasian admixture 18. Some groups (for example, African-American,
Caribbean and Panamanian populations) are likely to show a large degree of allelic
diversity, whereas other groups (for example, sub-Saharan Africans, Inuits and Finns) are
less genetically diverse. Old Amish individuals share more alleles than do individuals in
other populations because they marry within their own community and as a result have a
higher than-average incidence of inborn errors of metabolism 19, as do some Arab
consanguineous communities. Because of founder effects and enforced segregation,
Ashkenazi Jews also share a large number of alleles.134
Much more subtle, the field of epigenetics is demonstrating that environmental exposures and
lifestyle choices—again, factors highly influenced by social, cultural and geographic
groupings—impact gene expression in a heritable manner without changes in DNA.135
Proponents also emphasize the potential good that could be done for the populations of
developing countries, while also improving the safety and efficacy of biopharmaceuticals across
subpopulations in developed ones, by recognizing the disparate impact pharmaceuticals have on
subpopulations organized by race, ancestry, and ethnicity in advance of their market
distribution.136 They emphasize that, today, the measures for market access in the United States
are crude—the standard is better than placebo, biopharmaceuticals are often put on the market
with a showing of efficacy in only thirty-percent of the subjects, and usually only after being
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See generally Race, Ethnicity, and Genetics Working Group, The Use of Racial, Ethnic, and Ancestral
Categories in Human Genetics Research, 77 AM. J. HUM. GEN. 519-32 (2005); See generally Cohn, Lessons, supra
note 9; Bhopal, Responsible Use, supra note 9; Burchard, Importance of Race, supra note 9.
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Daar & Singer, Pharmacogenetics, supra note 105, at 242.
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See supra notes 22 & 53 and accompanying text. [Damon, please research tangible successes in epigenetics
research to date].
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See, e.g., id.
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tested on the general populations of Europe and North America.137 And, in fact, countries
largely excluded from biopharmaceutical R&D are responding by establishing their own
ancestry-based genotyping initiatives—countries including China, India, Indonesia, Japan Korea,
Malaysia, Mexico, Nepal, the Philippines, Singapore, Taiwan, and Thailand138—and even
transnational efforts, such as The Pan-Asian Initiative.139
C. The Debate Applied: HapMap and BiDil
One of the most controversial research undertakings in recent years is the International
Haplotype Mapping Project (“HMP”),140 a collaboration among scientists and funding agencies
from Canada, China, Nigeria, the United Kingdom, and the United States.141 The goal of HMP
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Id. at 243. The number of adverse events and performance disappointments with biopharmaceuticals in recent
years speaks to this. See generally Congressional Committee Report (Dec. 2007); Institutes of Medicine Report
2006; General Accountabililty Office Report (2006).
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Populations outside of North America and Europe are recognizing the problems of exclusion and potential
benefits of inclusion in biopharmaceutical R&D, and they are undertaking initiatives, sometimes in collaboration:
India and Thailand are both embarking on SNP-genotyping studies. Hosted by the Genome Institute of
Singapore, an important regional initiative has recently brought scientists from China, India, Indonesia,
Japan, Korea, Malaysia, Nepal, the Philippines, Singapore, Thailand and Taiwan to establish the Human
Genome Organization (HUGO) Pacific Pan-Asian SNP Initiative, which is expected to begin in the middle
of 2005. The goal of this initiative is to uncover the breadth of genetic diversity and the extent of genetic
similarity within Asian populations. This information will form the basis for future studies in genomic
medicine focused on Asian populations. Data from the Pan-Asian study will provide a platform for
researchers in Asia to study why some populations seem predisposed to certain diseases, or do not respond
to certain drugs. Cost reductions and new technologies are opening up the study to all researchers,
including those with less well-developed research infrastructures. Asia is not alone in such initiatives.
Mexico has a newly-created, well-funded federally mandated Institute of Genomic Medicine, headed by
Gerardo Jimenez-Sanches. Genotyping the diverse Mexican populations is one of its top priorities.
Daar & Singer, Pharmacogenetics, supra note 105, at 242.
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See supra notes 112-117 and accompanying text.
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For more information, visit the official site of the International Haplotype Mapping Project, at
http://www.hapmap.org/ (last visited June 2, 2007) and the National Human Genome Research Institute (NHGRI)
HapMap Page, http://www.genome.gov/page.cfm?pageID=10001688 (last visited July 12, 2007). See generally
Clayton, Implications, supra note 34; Ossorio, Haplotype Mapping Project, supra note 34.
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Visit Haplotype site, supra note 34; NHGRI HapMap Page, supra note 35. See generally Daar & Singer,
Pharmacogenetics, supra note 105, at 242.
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is to take the concept of familial-pedigree studies up to the population level—to compare genetic
sequences to identify chromosomal regions where genetic variants are shared, and to identify
clusters of variations that are inherited together.142 Stage I of HMP, commenced in October
2002 and completed in fall 2006, consisted of analyzing DNA from populations with African,
Asian, and European ancestry.143 This chapter of HMP resulted in a haplotype map consisting of
more than 1 million SNPs.144 The Consortium’s goal for Phase II, financed with $3.3 million in
public-private support, is to create a map five-times denser.145 Data is made available to the
global science communities on an ongoing basis through free public databases.146 HMP already
has enabled considerable population-based genetics research through its contributions to costeffectiveness.147
In addition to the science that HMP has generated, the project has made a tremendous
bioethics contribution to the field of population genetics and genetics research in general. HMP
has introduced a prototype ethics model for population genetics research with ancestry, race and

142

Visit Haplotype site, supra note 34; NHGRI HapMap Page, supra note 35.
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Samples were collected from 270 people in these three groups: Africans (30 sets of familial samples from the
Yoruba people of Ibadan, Nigeria); Japanese (45 unrelated individuals from the Tokyo area); Chinese (45 unrelated
individuals from Beijing); and Europeans (30 trio samples from European-Mormon families in the U.S.). Visit
Haplotype Mapping, supra note 52.
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NIH News Release, International HapMap Consortium Expands Mapping Effort (Feb. 7, 2005), available at
http://www.genome.gov/13014173 (last visited May 27, 2007).
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See id. This support includes the Wellcome Trust, London, $624,000; Genome Canada/Genome Quebec,
$260,000; Bristol-Myers Squibb Co., New York, $100,000; Pfizer Inc., New York, $100,000; Perlegen Sciences, at
least $1.2 million (based on "in kind" services); and NHGRI, $1 million. Id.
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the NIH-funded National Center for Biotechnology Information's dbSNP,
http://www.ncbi.nlm.nih.gov/projects/SNP (last visited June 6, 2007), and the JSNP Database in Japan,
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See generally Daar & Singer, Pharmacogenetics, supra note 105, at 243-244.
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ethnicity implications. 148 The Ethics Committee for HMP, co-chaired by Professors Ellen
Wright Clayton and Bartha Knoppers, has generated guidance and algorithms used in the project,
which include obtaining group consent when practicable and appropriate.149
Another significant controversy in race-based genetics that has raised the volume of the
debate was the Food and Drug Administration’s approval of BiDil for treatment of heart failure
specifically in African Americans (“blacks” is used on the label insert).150 The decision, issued
on June 23, 2005, was the first FDA approval of a pharmaceutical use limited to a specific racial
or ethnic group.151 The drug did not originate from a race-based population genetics
methodology,152 but it was approved based upon one—a study of 1,050 self-identified black
patients with severe heart failure who had already been treated with the best available therapy.153
According to the FDA, this study demonstrated that black patients on BiDil experienced a forty148

See generally, Implications, supra note 35. The HMP also has a staff committed to related ethical, legal, and
social implications issues, which includes Vivian Ota Wang, Jean McEwen and Lisa Brooks. The staff may be
contacted at:
National Human Genome Research Institute
National Institutes of Health
5635 Fishers Lane
Suite 4076, MSC 9305
Bethesda, MD 20892-9305
Phone: (301) 496-7531
Fax: (301) 480-2770
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See generally Clayton, Implications, supra note 35. See supra note 17.
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See supra note 112 and accompanying text. According to the BiDil package insert, “BiDil is indicated for the
treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to
prolong time to hospitalization for heart failure, and to improve patient-reported functional status.” BiDil Package
Insert at p. 9 (on file with author).
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three percent reduction in death, a thirty-nine percent decrease in hospitalization for heart failure
compared to a placebo, and a decrease of heart failure symptoms.154 Although the BiDil
sponsor’s methodology, data, and patent practice were challenged and criticized intensely in the
law literature,155 the FDA’s decision stands and the underlying data has survived scientific and
clinical scrutiny from the medical and science communities.156
Nevertheless, challenges from the law and social science communities linger. One
concern is that, because members often identify with racial and ethnic groups strongly, they will
demand drugs associated with their racial and ethnic group affiliations regardless of other good
medicine considerations and options, and physicians will give into those demands.157 Such a
scenario could exacerbate standing differences in health care quality due to race-based medicine,
as documented by the Agency for Health Care Research and Quality (AHCQ).158 Another is that
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Professor Jonathan Kahn has challenged the integrity of re-analysis of the general population trial data and the
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See AHRQ, National Health Care Disparities Report 2006 (2006), available at
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the biopharmaceutical sector will accomplish the same commercial responsiveness through
aggressive marketing, thereby exploiting racial and ethnic groups and detracting from their
health care.159 Professors Lillquist and Sullivan suggest that the medical community will not
move beyond race-specific data—meaning they will not engage in significant off-label use in
patients with the disease but without the race affiliation—to the potential medical disadvantage
of other populations.160 Others worry about the success of BiDil encouraging more race-based
research and exploitation of groups associated with the clinical study on African Americans.161
Dr. Jay Cohn, Director of the Rasmussen Center for Cardiovascular Disease Prevention at
the University of Minnesota and a renowned clinical researcher, has responded to these
challenges to BiDil with arguments based in science and a focus on good medicine.162 Dr. Cohn
was the lead investigator and inventor on a patent for BiDil (combining isosorbide dinitrate and

BUS. WK. 72-84 (May 29, 2006). Presumably, over time, increased precision from genomics will spill into medicine
and lessen these disparities.
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Question and answer session of Race-Based Research Session, Health Law Teachers Annual Meeting (June
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the safety and efficacy of its drug in the general population, which proved unsuccessful. FDA approval for use in
the general population accompanied with the release of data suggesting greater efficacy in African Americans would
have proven a more profitable market strategy, but one not supported by the clinical data. See supra notes 111-112
and accompanying text. It is unlikely that biopharmaceutical companies will intentionally limit the scope of their
market approvals, for they have been hesitant even to introduce pharmacogenomic data out of fear that the use of
their products will be conditioned on genetic screening and the presence of particular genetic alleles. See generally
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hydralazine).163 As stated by Dr. Cohn, from the perspective of a medical doctor and clinical
investigator,
The debate . . . should not be over the existence of population differences, but
how to describe those differences with more precision. Those who argue against
our current approach may wish that differences did not exist, but they do. They
are identified by statistical differences among definable populations in prevalence
and physiological mechanisms. These population differences cannot in the first
instance be classified as genetic, geographic, or environmental. They are observed
differences in populations identified by a variety of demographic criteria. Railing
against what some claim are misguided efforts to use racial, ethnic, or geographic
distinctions does not make the differences disappear. We should be working
toward better approaches in dealing with the differences, not raising legal and
moral arguments, as Professor Roberts has, claiming that any effort at distinction
is wrong.164

IV.

An Illustrative Case Study in Population Genetics
Responsible biobanking in any group introduces the potential to benefit the group under

study regardless of how that group is organized. These benefits include opportunities to increase
the level of communication between the group and the research community to raise sensitivity to
the group’s particular social and cultural norms, to participate at the forefront of genetics
research, to control the terms of that participation, and to realize commercial benefits and
scientific and medical returns. More generally, the endeavor advances bioethics through
population genetics case study applications and, scientifically and medically, introduces the
possibility of benefiting humankind well beyond the group under study due to the youth and
genetic sameness of our species.
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To illustrate these points, the scientific complexities and unpredictability of population
genetics, and the potential benefits of any serious, responsible population genetics undertaking,
consider the incidents of dwarfism embodied by Matt Roloff, his wife Amy, and their son Zach.
The Roloff case study places population genetics in a tangible context that utilizes a genetic
disease-based organizing criteria much more acceptable to opponents of race and ethnicity based
genetics research. The case study also is responsive to some of the fundamental challenges to
race and ethnicity-based genetics research raised by these opponents. First, it demonstrates the
extent to which groups organized by genetic disease may be no more homogenous than groups
organized by race and ethnicity, and even less so. Second, this case study underscores that,
regardless of the collection criteria, responsible biobanking may be advantageous on multiple
levels, including group communication, empowerment, and benefits.
Matt, Amy, Zach are dwarfs who are featured in the television show “Little People, Big
World” along with Zach’s siblings—Jeremy, Molly, and Jacob—who do not have dwarfism.165
To the casual observer, the Roloffs represent an extreme in genetic homogeneity given their
biological ties to each other and the incidence of dwarfism in their immediate family. Many
would be comfortable extending this perceived genetic grouping to encompass other people with
165

For information about the show and the Roloff family, visit the Roloff Family internet site at
http://www.mattroloff.com/ (last visited June 9, 2007). Slide Show, Dwarfism,
http://www.mansfield.osu.edu/~jbradley/102Ppts/Dwarfism.ppt. (last visited Feb. 7, 2007). Information about DD
is available at Little People of America Online, FQs, http://lpaonline.org/resources_faq.html (last visited May 28,
2007); Luise Bonafe & Andrea Superti-Furga, Diastrophic Dysplasia, (posted Nov. 15, 2004), available at Gene
Review, http://www.genetests.org/query?dz=diastrophic-d (last visited May 24, 2007). See also PBS, What is
Dwarfism, available at http://www.pbs.org/pov/pov2005/bigenough/special_dwarfism.html (last visited Apr. 16,
2007).. See generally PBS, “Big Enough”, aired Aug. 8, 2006; Clinical Implications of Basic Research: The
Genetic Basis of Dwarfism, NEW ENG. J. MED., vol. 332, no. 1, 58-59 (Jan. 5, 1995). Information about
achondroplasia dwarfism is available at Clair A. Francomano, Achondroplasia, available at GeneReviews,
http://www.geneclinics.org/profiles/achondroplasia/details.html (updated Jan. 9, 2006) (last visited Feb. 7, 2007);
March of Dimes, Quick Reference and Fact Sheets: Achondroplasia, available at
http://www.marchofdimes.com/professionals/681_1204.asp (last visited Feb. 7, 2007). The popularity of Little
People, Big World has inspired “The Foos Family,” the real TV profile of a family with dwarfism throughout. For
information about the Foos, visit http://www.advancedmedical.tv/shows/mtf.htm#synapsis (last visited Apr. 14,
2007).
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dwarfism given that it is commonly recognized as a genetic condition. However, there are more
than two hundred forms of dwarfism, which appears throughout recorded history and affects both
sexes and all races.166 Matt has diastrophic dysplasia (“DD”), the third most prevalent type of
dwarfism, which occurs once in every 110,000 births in the U.S.167 Although DD arises in all
races and sexes, there is a higher incidence rate in Finland.168 Symptoms associated with DD
include a cleft pallet, a “hitchhiker thumb” (a thumb permanently distended), club feet, and other
orthopedic and joint problems that impact shoulders, elbows, hips and knees.169 The gene for
DD, SLC26A2, is on chromosome 5q32-q33.1 and it is recessive. 170 A parent may carry the
gene but not have DD, and both parents must carry the gene—not necessarily have DD—to have
a child with DD.171 Typically, children with DD are born to two parents who each carry the DD
gene but do not have DD. 172 Under these circumstances, there is a fifty percent chance that each
child will be a carrier of DD but not have dwarfism, a twenty-five percent chance that the child
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will have DD (have a pair of SLC26A2 genes, one from each parent), and a twenty-five percent
chance that the child will be unaffected.173
Matt’s wife Amy and son Zach have achondroplasia (“AP”), the most prevalent form of
dwarfism, which occurs in one out of every 25,000 births and, like DD, affects both sexes and all
races.174 However, the gene for AP, FGFR3, is dominant, so it is symptomatic in everyone who
carries FGFR3.175 Eighty percent of AP children are born to parents of normal stature, meaning
that AP usually is the result of a de novo gene variation.176 When both parents have AP, each
carries the FGFR3 gene and its non-AP counterpart, meaning that they have a fifty percent
chance of having a child with AP (one FGFR3 gene paired with a non-AP counterpart), a twentyfive percent chance of having a child without AP (two non-AP genes), and a twenty-five percent
chance of having a child with two FGFR3 genes.177 This latter condition, known as homozygous
AP or double homozygosity, usually is fatal.178
The Roloffs had no chance of having a child with DD because Amy is not a carrier of
SLC26A2.179 Matt does not have AP and does not carry FGFR3. Therefore, with each
pregnancy, Amy and Matt had a fifty percent chance of parenting a child with AP, and all the
Roloff children—including Jeremy, Molly, and Jacob who are of normal stature—are carriers of
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DD.180 Among Matt, Amy, and Zach, all are dwarfs according to phenotype and, therefore, they
share many challenges posed by their environment on a daily basis—for example, extreme stress
on their hips and knees due to the size of their heads and torsos in relation to their limbs. Their
symptoms overlap significantly, though some are distinguishable—for example, the severity of
Matt’s joint and orthopedic problems associated with DD, which cause him to rely upon walkers
and occasionally electronic ambulatory machinery for movement.181 However, genetically, their
DD and AP differences make them highly distinguishable. Combining these fundamental
genotype and phenotype characteristics, there is a lot of genetic complication within the Roloff
family: according to phenotype, three incidents of dwarfism among a family of six, with both
overlapping and distinguishable symptoms; two forms of dwarfism with completely different
genetic causes, one a dominant gene and the other a recessive gene, on different chromosomes;
and four children who are carriers of DD, including three who are of normal stature.182
Although the societal perceptions used to group the Roloffs and people with dwarfism in
general are at best an exaggeration of genetic reality, the Roloffs could advance the realization of
bioethics principles in population genetics and make significant contributions to genetics
research in and beyond dwarfism. Imagine that the Roloffs decide to use their celebrity to
advance research on dwarfism by establishing littlepeopleBiobank (“lpBiobank”), a biobank of
families in the U.S. with at least one occurrence of a child with dwarfism.183 Little people with
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dwarfism in the United States are highly organized on the national, regional, and local levels
through the not-for-profit organization Little People of American (“LPA”), and they share strong
social group identification.184 Throughout its half-century of existence, LPA has united the
community through its many social activities, including conferences and other events, and by
serving as an information resource. 185 LPA has earned the trust of its members, as evidenced
through their active and ongoing participation.186 The organization of the group and its
governance structure suggests a means to work through bioethics issues such as individual
consent, group impact, and group consent with sensitivity and insight.187 LPA also could
provide a means to identify acceptable conditions for research protocols and workable terms for
technology transfer around the lpBiobank, such as the requisite quid pro quo for researcher
access.188 Presumably the scope of the lpBiobank, both in terms of samples and accompanying
medical information, and the sophistication of its organization and ability to meet individual
researcher needs would be somewhat proportional to the group’s bargaining power with
researchers and research institutions.189

the United Kingdom Representatives from these biobanks were gathered in August 2007 for the Meeting to Launch
the Taiwan Biobank, in which the author participated. Proceedings, Meeting to Launch the Taiwan Biobank,
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If lpBiobank were formed, the basic phenotype characteristics associated with dwarfism
would unite people who embody a range of distinct genes that cause their distinguishable version
of the condition—meaning a phenotypically homogenous group, idiosyncratically so to the
layperson, that actually embodies a lot of genetic diversity.190 It is theoretically possible that
there could be less overall genetic commonality among the lpBiobank members than among
another group that, based on phenotype, appears more genetically diverse to society. For
example, there may be more genetic commonality among the one hundred and seventy-five 1Ls
at Yale Law School, a heavily screened group selected, among other things, to achieve diversity
as defined by society (or at least law school administrators).191 Greater genetic commonality
might also be found between the subpopulation of the lpBiobank with DD and the Yale 1Ls, for
SLC26A2 is but one of the 3,000,000 distinct DNA variants estimated to separate any two
unrelated human beings.192 Similarly, the females in lpBiobank may share more overall genetic
commonality with the first year class at Wellesley College, an all-women school, than with their
male lpBiobank co-members. Also, given the higher incidence of DD in Finland, the DD
members of the group may share more overall genetic commonality with the population of one
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text.
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or more of the small, scattered, isolated settlements in Northern and Eastern Finland than with
their lpBiobank counterparts.193
Nevertheless, lpBiobank may prove a valuable resource to develop bioethics algorithms
for researchers working on DD and AP and population genetics in general. Moreover, even if
the lpBiobank membership were limited to people with DD and AP dwarfism, researchers
working on other forms of dwarfism also may take interest because some of the more
fundamental phenotype characteristics (shared cellular differentiation) of dwarfism transcend the
groupings. Comparing and contrasting the expression of a particular phenotype characteristic
among subpopulations in the lpBiobank could prove a means for identifying and understanding
the intricate pathways of gene and cellular expression that connect the common phenotype
characteristic to the highly distinguishable genetic triggers for dwarfism. In fact, because
members of the human species are 99.9 percent the same genetically, the lpBiobank could prove
useful for a wide array of genetics research not necessarily associated with dwarfism depending
on how extensive the biobank is and the type and quantity of medical information available to
researchers. It follows that research findings by those working within the lpBiobank may readily
transcend the DD population—for example, fundamental understanding about genetic expression
and cellular differentiation in the general human population. Moreover, in addition to any direct
benefits to members of lpBiobank, the endeavor could contribute immensely to population
genetics in general through development of thoughtful recruitment, consent algorithms, and
technology transfer precedents. Working within a group defined by society that self-identifies
would provide a means to insightful deliberation of group impact. LpBiobank also might
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contribute to genetics research and society in general by inspiring similar biobank efforts among
other groups, thereby creating resources needed to accelerate the process of making medical
sense out of the human genome map.

V. A Proposal in Favor of Race-Based Genetics Research
The reckless words of Dr. Watson published by the London Sunday Times on October 14,
2007194 speak to the dangers of using social science to make conclusions about human genetics
that are not substantiated by existing genetic science.195 This is a lesson learned over the last
century at tremendous cost to human life, extraordinary human suffering, and incalculable lost
research opportunities when Charles Davenport, a Cold Spring Harbor predecessor of Dr.
Watson, established the Station for Experimental Evolution at Cold Spring Harbor and the
Eugenics Record Office next door.196 Dr. Davenport used Cold Spring Harbor and the Eugenics
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Record Office to collect shoddy data that substantiated centuries of social observation about the
human condition, however tainted by prejudices.197 His work gave credibility to a eugenics
movement that started with a sputter of “fitter families contests” in America’s heartland but then
roared into an international movement that included involuntary sterilization legislation and
forced sterilizations in the United States and beyond, provided some precedent for the murder of
millions the Third Reich deemed “undesireables”, and served as a pretext for the torture of tens
of thousands, including many children, under the guise of medical research.198
The immediate outrage of today’s genetics and broader natural science communities in
response to Dr. Watson’s comments and the global resonation of that protest attest to the extent
to which the field of human genetics has evolved over the last century, even if some of Dr.
Watson’s thinking has not.199 The lines between natural science in genetics and the social
sciences must be respected. Crossing them is essential, but that must be done with
thoughtfulness and professionalism—for example, the Ethical, Legal, and Social Implications
Program counterpart to HGP.200 Just as social science findings should not be substituted for
established genetic science truths, the legitimacy of responsible genetic science research should
not be undermined scientifically where the driving force is actually to preempt avoidable social
harms. There simply is too much potential benefit to human health at stake to make the lines that
for research in United States universities, while the Records Office was financed through generous support from Ms.
Mary Harriman, a philanthropic socialite. Id. at notes 33-35.
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faint and fluid. Identifiable and ominous potential social harms necessitate caution, but the
answer is to move research forward thoughtfully and responsibly with the strong presence of
responsive law and policy.
As articulated thoughtfully by Dr. Raj Bhopal,201 “Race and ethnicity are closely related,
contentious concepts that have been abused and misinterpreted through history, but have a vast
potential for good, at least in the health sciences.”202 Similarly, as observed by Dr. Margaret
Winker, Deputy Editor of the Journal of the American Medical Association, “Despite the many
difficulties posed by categorizing race, in some instances it can be important to assess race and
ethnicity.”203
Race and ethnicity are as real socially and culturally as genetics is scientifically204 and
“[i]t is well known that disease does not affect the population equally[.]”205 The reality of these
constructs is made evident by the reactions they compel, their impact on human history, and their
influences on culture, society, and how individuals perceive themselves and others.206 Race and
ethnicity influence where people live, how they live, what they consume, and whom they partner
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and propagate with—often significantly.207 Moreover, they have done so for many generations;
historically, race and ethnicity have profoundly impacted what environmental exposures people
have been subjected to, and their influence continues. “Put simply, place has a huge impact on
health for a variety of reasons. Indeed, increasing globalization may weaken the cumulative
effects that place has on health. Nonetheless, many people still reside and work in the same
place for many years. This pattern is particularly pronounced in rural areas.”208 Moreover, the
populations of developing economies more heavily influenced by ancestry, race, and ethnicity
than the population in North American Europe have been largely excluded in biomedical R&D
even when they are recipients of resulting biopharmaceuticals, and many of their most pressing
health care needs continue to be unmet and relatively low priorities in ongoing biomedical
R&D.209
Completion of the map of the human genome has raised appreciation for the extent to
which, especially over time, shared environmental exposures can make a collective genetic
difference—perhaps most notable through advancement in the field of epigenetics.210 The map
has illuminated a universe of intricacies, complexities, and subtleties in human genetics beyond
the appreciation of most prior to its completion.211 Consequently, the map has shifted
perspective and increased comprehension of the influence of environment exposures in the study
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of gene expression, and it has inspired research within populations grouped over time by social
and cultural notions of race and ethnicity.212
The approach is supported by significant past success engaging in genetics research
within groups identified by the social constructs race, ethnicity, and religion, including the
country members of The Pan Asian Initiative and their populations,213 as well as populations of
Ashkenazi Jews, Amish, and Mormons within the U.S.214 There are ample examples of disease
rate differences documented with sound epidemiological data that correlate with groupings based
upon race and ethnicity.215 The intricacies of human genetics have shifted much genomics
research up to the population level on par with traditional epidemiological research.216
Moreover, biotechnology has begun to introduce a generation of biopharmaceuticals developed
around specific genetic alleles,217 including precedent for developing and delivering medicines
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with attention to genetic differences that are associated with race.218 Race-based research is
generating results—increased understanding about diseases, such as MS,219 and the means to
make biopharmaceuticals help and avoid harm in groups organized by race and ethnicity.220
The law and social science opponents to race-based genetics research challenge the
soundness of the underlying science.221 They also draw heavily from the legacy of use of
classification based upon race and ethnicity, both inside and outside of the biomedical context, to
discriminate and exclude and, when combined with science, to exploit and affirm racist notions
of inferiority.222 Rounding up and focusing upon this legacy, a strong argument can be made that
the social dangers of race-based genetics research are too great to justify, especially given
alternative research methodologies—most notably, disease based and allele-specific population
genetics.223
Incendiary debate and ongoing critiques, especially in an age of global communication
and unprecedented transparency, police use of race-based genetics research and the integrity of
associated research.224 The professional consequences to Dr. Watson from his words attest to the
same.225 This check accompanies a trilogy of considerations that support responsible race and
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ethnicity-based genetics research, each of which is discussed below. First, strict adherence to
thoughtful application of bioethics law and policy demands maximum communication with
potential research subjects and full consideration of the impact of proposed research on study
participants.226 Recognition of race and ethnicity from the individual subject’s perspective—
sensitivity towards an individual’s association with a particular race and the impact of race and
ethnicity on one’s self-identification—is fundamental to maximize communication and fully
assess the impact upon potential subjects, both individually and collectively.227 Second, directly
recognizing, addressing, and understanding race and ethnicity is a means to confront and offset a
legacy of discrimination through responsible inclusion in biomedical research, which is
consistent with the pragmatic exercise of sample collection so necessary in an age of population
genetics.228 Third, advancement of responsible race and ethnicity-based genetics research is
consistent with the science arguments of its opponents as well as its proponents.229

A. Bioethics
The National Institutes of Health (NIH), the Food and Drug Administration (FDA), and
institutional review boards (IRBs) should scrutinize research protocol proposals for race-based
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genetics research and oversee the research they enable to ensure compliance with regulations to
protect human subjects.230 Existing law requires nothing less.231
The regulations to protect human subjects favor race consciousness over race neutrality in
fundamental ways. First, population genetics necessitates the collection of large numbers of
samples with accompanying medical information.232 The connection to medical information
means that samples are identifiable, even if encrypted, which triggers the informed consent
requirement.233 Voluntary, informed consent is the touchstone tenet of applied bioethics, as
recognized in the Nuremberg Code,234 Declaration of Helsinki,235 and Belmont Report,236 and as
codified in U.S. law under the Common Rule237 and FDA regulations.238
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Field Code Changed

The realization of informed consent presupposes meaningful communication—a meeting
of the minds between study sponsors and subjects.239 Recognition of race and ethnicity from the
individual subject’s perspective—sensitivity towards whether the individual self-identifies with a
particular race or not—is fundamental to maximize communication and to fully assess the impact
upon potential subjects, both individually and collectively. As explored through Critical Race
Theory in the law literature for decades240 and in the social sciences for much longer,241 race and
ethnicity often have a profound impact on how people self-identify, interpret information, and
relate with others and society in general.242 “Arguably, classifying people using large-scale
categories such as `African-American’ or `Native American’ can be helpful in understanding
community practices with respect to external sources of care, because such practices are based
on conditions of discrimination and economic disparity that are more or less consistent
throughout the United States.”243 An interesting recent phenomenon that underscores this point
is the receptiveness of African Americans to genetic ancestry services, which has been explained
as a desire to bridge the gap in recorded ancestry attributable to slavery.244
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In addition to individual consent, HMP and other population genetics efforts have raised
recognition of the importance of group consent, and HMP has generated some algorithms for
obtaining it.245 Group consent is necessitated by the reality of group harm. In fact, the National
Geographic Society’s project to collect 100,000 indigenous DNA samples to trace migrations
patterns of the human species, the Genographic Project, was suspended while an Institutional
Review Board at the University of Pennsylvania worked on the informed consent process.246
Directly addressing race and ethnicity in population genetics is a means to fully assess group
impact, including group harm, and to develop this second dimension of consent. 247
Bioethics also demands full deliberation of the racial and ethnic composition of study
subjects. Specifically, the Common Rule and NIH regulations incorporate the fundamental
ethics principles identified in the Belmont Report. 248 Justice, the second of the three principles,
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demands recognition of race and ethnicity for research impact assessment and that such
assessment be undertaken. As explained in the Report,
[T]he selection of research subjects needs to be scrutinized in order to determine
whether some classes (e.g., welfare patients, particular racial and ethnic
minorities, or persons confined to institutions) are being systematically selected
simply because of their easy availability, their compromised position, or their
manipulability, rather than for reasons directly related to the problem being
studied. Finally, whenever research supported by public funds leads to the
development of therapeutic devices and procedures, justice demands both that
these not provide advantages only to those who can afford them and that such
research should not unduly involve persons from groups unlikely to be among the
beneficiaries of subsequent applications of the research.249
In accordance with the justice principle, NIH rules require researchers to describe the
composition of study populations and to provide a rationale for subject selection.250 The realities
of race and ethnicity are utilized to police against discrimination and exclusion, the very
concerns fueling opposition to race-based genetics research.251

B. Research Pragmatism and a Means for Access
The social constructs of race and ethnicity, like genetic science, are neither intrinsically
good nor bad. Their social impact depends upon how they are used. The ethical, legal, and
social legacies of race and genetics are damning,252 especially at their nexus, which mandates
caution moving forward.253 However, learning from the past and proceeding with caution must
be distinguished from allowing the past to control the future, especially when the context is
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human health and there are opportunities to include where there has been exclusion, to lessen
health care disparities, and to improve human health.254
Making medical sense out of the map of the human genome map necessitates accessing
samples and medical information.255 Race and ethnicity are strong influences on how
populations are organized and self-identify,256 especially in developing economies, 257 and
utilization of such groupings could provide a means for the extensive sample collection
necessary to advance the translation of the map into medical meaning.258 Research pragmatism,
the simple act of approaching and interacting with populations to collect needed samples and
accompanying medical information on acceptable terms, favors recognizing and embracing race
and ethnicity. Moreover, groups organized by race and ethnicity, such as country participants in
The Pan Asian Initiative, have an unprecedented opportunity to leverage their organization to
draw research to their priority areas, and do so on terms favorable to them.259 Research
contributions are being made, such as enablement of the MS study mentioned earlier260 and racebased research to improve the efficacy and safety of biopharmaceuticals for the groups
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involved.261 “Racial and ethnic categories can be particularly important in securing resources to
reduce structural barriers to prevention and care, especially where racial and ethnic categories are
embedded in health care and research infrastructure and policy.”262 Globally, the need for
change could not be greater: “Only 16 of the 1,393 new drugs that were marketed between 1975
and 1999 were registered for diseases that predominantly affect people in developing countries,
and through of those were for tuberculosis, which is not restricted to developing countries.”263
Singling groups out on the basis of race and ethnicity to benefit their health is desirable,
presumably a legitimate state interest, and not discrimination for the purposes of U.S.
antidiscrimination jurisprudence.264 It follows that, within the discipline of law, race and
ethnicity in genetics research should be approached with the mindset of responsible bioethics and
affirmative action/inclusion, not with a presumption of discrimination. We should think openly
in terms of race and ethnicity to raise participation in the genomics revolution. Professor
Hoffman’s proposed attributes-based identification runs contrary to a function-based approach to
affirmative action, which is premised upon recognizing race meaningfully in order to accomplish
objectives such as inclusion and diversification.265 “Prohibiting the use of racial identity labels
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and ignoring prejudice and discrimination will not make them disappear. The very persistence of
discrimination creates a need for a tool to monitor and redress its effects.”266

C. The Underlying Science
Race-based research is producing results—results that include increased understanding of
diseases such as MS and explanations for the prevalence of adverse events from common
biopharmaceuticals in populations organized by race and ethnicity.267 Nevertheless, ironically,
advancement of responsible race and ethnicity-based genetics research also is consistent with the
scientific arguments of its opponents, as illustrated by the lpBiobank case study.268 To the extent
opponents are proven correct, research outcomes and associated health care applications will
transcend the racial and ethnic groups under study to benefit the entire human species.
Advancement of the research will establish the extent to which race and ethnicity are genetic
fictions. Groups organized by race and ethnicity will gain the opportunity to bargain for
inclusion with both the science and medical communities, and the doctrine of group consent will
be further developed.269 To the extent the critics are incorrect, the groups under study will
benefit disproportionately through scientific understanding and greater likelihood of medicinal
applications tailored to their genetic idiosyncrasies.
The law, bioethics, and social science communities have raised concerns that the fluidity
of race and ethnicity make them scientifically imprecise enough to necessitate regulating them
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away from many biomedical research purposes.270 These concerns embody several
presumptions about the natural science communities. First, they presume that the natural science
communities are incapable of accounting for the imprecision of what they recognize to be social
constructs.271 Second, they presume that the natural science and medical communities are not
capable of policing the validity of scientific claims that arise from race and genetics-based
research and engaging in meaningful, ongoing peer review. In fact, the natural science and
medical communities utilize peer review extensively, in contrast with legal academia, which
entrusts most journal publication selection and production to law students. Third, they presume
that it is not possible to carry out race and ethnicity based research with responsible application
of bioethics and sensitivity to group impact.
In fact, the immediate, definitive, and global response to Dr. Watson’s comments about
genetics and race272 and the rigorous debate over this research within the natural science and
medical communities suggest the contrary.273 The broader debate within the global science,
medical, bioethics, law, sociology, and other social science communities provides an even firmer
check on the integrity of resulting claims and the threat of abuse of science for social injustice.274
The role of law and policy in this debate should be to enforce regulations that protect human
subjects to ensure race-based genetics research is carried out in a responsible manner, meaning
with attention to consequences for individual subjects and the groups they represent.
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VI. Conclusion
Race-based genetics research is advancing understanding about human disease and
directly benefiting populations under study.275 Entire nations are organizing themselves to reap
these benefits, both individually and collectively.276
Law is largely a reflective endeavor; the precedent of the past is highly influential and
often persuasive. However, mistakes of the past should not determine the present nor the future
of genetic science and medicine, especially given the opportunities for inclusion and to improve
human health associated with responsible genetics research.277 Rather than allowing past
mistakes in scientific research and medicine and a legacy of discrimination and exploitation
based on race and ethnicity to shackle science, the law should be applied to ensure that research,
including race, ethnicity, and ancestry-based population genetics, advances responsibly.
This article has analyzed the use of race and ethnicity in genetics research with sensitivity
to past controversies and present inequities, but with an emphasis on applied bioethics, scientific
pragmatism, and ongoing biopharmaceutical R&D. A major theme is that the lines between
natural genetics science and the social sciences should not be made too faint and fluid. Doing so
from the base of natural genetic science invites speculation about genetic truths and introduces
susceptibility to prejudices. Doing so from the base of the social sciences invites overreaching
far beyond the existing state of genetic science and the substitution of speculation for scientific
reality in areas fundamental to human health and society.
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The article’s proposal promotes several important goals: heightened sensitivity towards
people’s self-identification, group identification, and group impact in the context of population
genetics research on human subjects;278 an increase in the rate of translation of the map of the
human genome into medical meaning through more group participation in biomedical
research;279 an increase in participation in the genomics revolution by groups organized socially
and culturally by race and ethnicity;280 and a lessening of negative, documented disparities in the
delivery of health care for these groups.281
Responsible race-based research is possible and desirable, and the law should be applied
to accomplish nothing less. This position rests solidly on footings of applied bioethics,282
research pragmatism, 283 and natural science.284 Proposals to stretch U.S. antidiscrimination
jurisprudence to regulate away the use of race and ethnicity in genetics research are misguided at
best.
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